BACE-1 inhibitors: from recent single-target
molecules to multitarget compounds for Alzheimer’s
disease
Federica Prati, † Giovanni Bottegoni, ‡δ Maria Laura Bolognesi, § and Andrea Cavalli* ‡§
†Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life
Sciences, University of Dundee, Dow Street, Dundee, DD1 5EH, Scotland, UK
‡CompuNet, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy
δHeptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire,
AL7 3AX, UK
§Department of Pharmacy & Biotechnology, Alma Mater Studiorum-University of Bologna, Via
Belmeloro 6, 40126 Bologna, Italy
KEYWORDS: Neurodegenerative disease, neurological disorder, amyloid hypothesis, tau
hypothesis, structure-based drug discovery, fragment-based drug discovery
ABSTRACT. The amyloid hypothesis has long been the central dogma in drug discovery for
Alzheimer’s disease (AD), leading to many small-molecule and biological drug candidates. One
major target has been the β-site amyloid-precursor-protein-cleaving enzyme 1 (BACE-1), with
many big pharma companies expending great resources in the search for BACE-1 inhibitors. The
1
1
2
3
4
5
6
7
8
9
10
11
1213
14
15
16
17
18
1
lack of efficacy of verubecestat in mild-to-moderate AD raises important questions about the
timing of intervention with BACE-1 inhibitors, and anti-amyloid therapies in general, in AD
treatment. It also suggests new possibilities for discovering BACE-1-targeted compounds with
more complex mechanisms of actions and improved efficacy. Herein, we review the major
advances in BACE-1 drug discovery, from single-target small molecule inhibitors to multitarget
compounds. We discuss these compounds as innovative tools for better understanding the
complexity of AD and for identifying efficacious drug candidates to treat this devastating
disease.
1. Introduction
In 1992, Hardy and Higgins first outlined the amyloid cascade hypothesis, suggesting that
“amyloid-beta protein (Aβ) is the causative agent in Alzheimer’s disease (AD) pathology and
that neurofibrillary tangles, cell loss, vascular damage, and dementia follow as a direct result of
this deposition”.1
Twenty-five years later, this hypothesis, in its various incarnations, still appears to be the major
inspiration for AD drug researchers. This is despite the failures of recent high-profile clinical
trials, and an increasing number of dissenting opinions concerning the effectiveness of this
hypothesis. Indeed, several recent papers have captured the attention of the field by outlining
major inconsistencies and controversies related to this hypothesis.2,3 These include the presence
of Aβ deposition in cognitively healthy elderly people, the general discrepancies between plaque
density and the severity of dementia, the lack of comprehensive nominal, functional, and
structural descriptions of oligomeric Aβ assemblies, and challenges to the validity of amyloid
animal models.4
2
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
2
Nonetheless, the number of recent and ongoing clinical trials and preclinical investigations
shows that many research groups are seeking to develop small molecules that can modify the
generation, clearance, and/or toxicity of Aβ. These small molecule strategies compete with active
and passive amyloid-based immunotherapies,5 sharing with them a long history of clinical
failure.
In this respect, a recent analysis of failed phase 3 amyloidocentric agents (such as γ-secretase
inhibitors and Aβ-antibodies) points out how deficiencies in clinical trial design, as well as
liability of the pursued compounds ultimately compromised the success of the studies.6
Particularly, while some therapeutics were very unlikely to succeed due to lack of robust
preclinical data, others failed to establish adequate target engagement because of dose-limiting
site effects. Therefore, these agents did not show any clinical benefit, but neither allow to
unequivocally test and discard the mechanistic approach under investigation, as target
engagement was not measured. Hence, these considerations provide sustenance to those drug
developers and scientists who believe that the amyloid hypothesis has yet to be tested.
Big pharma’s favorite amyloidocentric AD target is the β-site amyloid-precursor-protein-
cleaving enzyme 1 (BACE-1), that is, the aspartic protease that cleaves amyloid precursor
protein (APP) at the β-secretase site. JNJ-54861911,7 CNP520,8 and LY32026269 (structure not
disclosed) are the three most recent BACE-1 inhibitors working their way through the trial
pipeline, while verubecestat 1 (MK-8931),10,11 (Figure 1) is the most advanced BACE-1 inhibitor
in clinical development. We expect other BACE-1 inhibitors to advance into clinical trials
resulting from the research described herein.
Several factors have likely contributed to the current preference for inhibiting BACE-1 rather
than Aβ aggregation. First, it is particularly challenging to develop small molecule inhibitors of
3
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
3
protein-protein interactions (PPIs).12 The regions of PPIs involve large contact surfaces (1500-
3000 Å), whereas the regions of protein-small-molecule interactions are only about 300-1000 Å.
In addition, the PPI regions generally lack cavities, i.e. grooves or pockets into which a small
molecule could dock in an energetically favorable manner. The binding energy that drives
protein-protein contacts is typically distributed over a large area that lacks a defined “hotspot”
for pharmacological intervention. Taken together, these inherent limitations severely restrict the
drug-likeness of Aβ aggregation inhibitors.
Conversely and for several reasons, BACE-1 appeared (at least initially) to offer bigger
opportunities and to be a more druggable target. First, effective aspartyl protease inhibitors had
already been developed successfully in other therapeutic areas, such as hypertension and HIV.13
Second, the first crystal structure, solved in 2000,14 seemed to support straightforward structure-
based (SB) approaches. In particular, BACE-1 is a monomeric protein with a bilobal structure,
which accommodates the catalytic aspartic dyad (Asp 32 and Asp 228) between the N- and C-
terminal domains. The rather large active site is sheltered by a β-hairpin loop, known as a flap,
which forms a large and flexible portion of the binding pocket. Spurred on by rising expectations
and boosted by the discovery of different peptidomimetic inhibitors with nanomolar activity,
researchers have been seeking to develop small molecule BACE-1 inhibitors ever since.15-18
However, progress has been hampered by the rigid prerequisites for any drug that is to treat a
chronic neurodegenerative disorder and by the uncompromising nature of the BACE-1 catalytic
site (see below).15 Selectivity towards different aspartyl proteases could be an additional factor in
the attrition rate for BACE-1 drug discovery.
Thus, two decades of research have shed light on additional layers of complexity that may take
many years to explore. Nonetheless, we will argue here that the bulk of data collected still
4
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
4
supports BACE-1 as a major target for AD drug discovery, both now and in the future. In
particular, we will consider new horizons such as the development of BACE-1 inhibitors with an
expanded therapeutic profile, and the use of BACE-1 inhibitors in a more promising personalized
medicine setting.
Clearly, the amyloid theory is not the only pathogenic hypothesis of a complex multifactorial
disease. Tau19 and prion20 have both been proposed to trigger AD and mediate its progression. In
addition, oxidative stress,21 neuroinflammatory22 and mitochondrial23 cascades appear to explain
the disease process and have been subject of considerable research and speculation.
To effectively confront such multifaceted and complex nature, several lines of evidence point to
multitarget compounds (often referred to as ‘multitarget-directed ligands’ (MTDLs)), which can
hit proteins in complementary pathways.24 In terms of BACE-1 inhibitors, this means developing
small molecules that can modulate both BACE-1 and other related targets. In principle, this
could considerably enhance efficacy and produce more satisfactory clinical outcomes.
In terms of personalized medicine, companion diagnostics have now entered the AD field, where
they should allow clinicians to precisely assess the benefits of anti-amyloid therapy and to
identify the “best patients” for a given treatment.25 For example, Merck is developing the BACE-
1 inhibitor 1 in conjunction with the FDA-approved amyloid PET tracer flutemetamol.
Flutemetamol will be used to identify patients who might benefit from 1 treatment and to
monitor clinical outcomes.
Herein, by critically reviewing the literature and systematically discussing the progress made, we
hope to address the open questions regarding the validity of BACE-1 as an AD target, and to
inspire the design of novel improved inhibitors. We will first review the recent advances in the
design and discovery of BACE-1 inhibitors. We will then consider the major computational
5
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
5
approaches used over the last decade to assist the design of BACE-1 inhibitors, mainly through
SB approaches made possible thanks to the existence of BACE-1 crystallographic structures. We
will conclude by reporting on MTDLs centered on BACE-1. These have the potential to become
next-generation BACE-1 inhibitors with improved efficacy in treating this devastating
neurological disorder.
2. BACE-1 inhibitors: an update
As highlighted above, the search for effective BACE-1 inhibitors for AD treatment has been a
hot topic in the past few years. The many reports in the literature have been covered by some
comprehensive reviews.15-18 Therefore, this section will focus on the most relevant medicinal
chemistry investigations carried out more recently.
Peptidomimetics were the first BACE-1 inhibitors to be reported. Despite their high in vitro
potency, they had inadequate pharmacokinetic (PK) properties, which generally made them
ineffective for treating AD. Peptidomimetics have long been a staple of BACE-1 inhibitor
research programs, with recent publications demonstrating that researchers are still interested in
them.26-29 However, the focus has mostly shifted to small molecule nonpeptide inhibitors.
Investigations into new small molecule nonpeptide inhibitors involve high-throughput, fragment-
based (FB), or virtual screenings, followed by chemical optimization. The primary goal is to
develop novel inhibitors that are smaller, with less of a peptide character, and an improved PK
profile.
However, the development of nonpeptidic BACE-1 inhibitors large enough to bind with
sufficient affinity to the enzymatic active site, yet small enough to exhibit satisfactory PK and
sufficient lipophilicity to sustain suitable brain penetration, has proven to be very challenging.16
6
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
6
Initially, inhibitor size reduction resulted in a decrease in BACE-1 inhibitory potency. However,
SB drug design strategies, supported by crystallographic data, led to high affinity BACE-1
inhibitors with additional and specific drug-target interactions. Improved central nervous system
(CNS) penetration was also achieved, trough enhanced blood brain barrier (BBB) permeability
and reduced P-glycoprotein (Pgp) efflux, by properly fine-tuning compound physiochemical
properties, such as polar surface area (PSA), molecular weight (MW), lipophilicity, number of
rotatable bonds and hydrogen bond donors (HBD).18,30,31 Off-target effects also needed to be
addressed, taking advantage of structural data and reflecting on physiochemical property
balancing. Importantly, potent small molecule BACE-1 inhibitors have lately been developed to
achieve satisfactory brain penetration and robust cerebral Aβ reduction with good safety margins
in preclinical animal models. In summary, high level of understanding to develop efficient in
vivo BACE-1 inhibitors has been obtained, and recent efforts, showing how research in the field
is making strides in the right direction, are discussed below.
2.1 Aminohydantoins, aminooxazolines, aminothiazolines, and iminopyrimidinones
A key advance in nonpeptide BACE-1 inhibitor design was the discovery of 2-amino
heterocycles that engage both of the Asp moieties in the BACE-1 active site.15-18 Compared to
initial acylguanidine inhibitors, these ligands generally enabled a better physical-chemical
profile, improved brain penetrance and in vivo efficacy.
Along this line, the aminohydantoin BACE-1 inhibitor 2 (Figure 2) was recently developed by
Merck. Although 2 was potent in the enzymatic assay (Ki = 22 nM), it suffered from a
pronounced cell shift when tested in whole-cell assay (cell IC50 = 258 nM), due to Pgp efflux. It
7
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
7
also showed modest oral bioavailability and lowered plasma, but not cortical Aβ40 levels in
CRND8 mice.32
Seeking to identify novel, highly soluble, and permeable BACE-1 inhibitors, Hunt et al. prepared
a collection of small, rigid, and saturated or partially saturated cores using 2-amino heterocycles.
This led to the identification of spirocyclic aminohydantoin 3 (BACE-1 IC50 = 36.8 μM) (Figure
3), which combines limited molecular flexibility with three-dimensionality,33 key factors for
permeability and solubility, respectively. The group conducted structure-activity relationship
(SAR) studies of core changes, P3 moieties, and warhead (WH) Asp-binding functional groups.
This provided compounds with double-digit nanomolar enzymatic and cell-based Aβ1-40
inhibitory potencies, but low selectivity with respect to the closely related aspartyl protease,
cathepsin D (CatD) (IC50CatD/IC50BACE = 0.2-97). (R)-enantiomers were roughly twice as potent as
the corresponding racemates, but did not consistently show increased affinity for CatD. Although
suitable alternative Asp binding moieties to eliminate efflux were not identified (the
aminohydantoin WH contributes to Pgp efflux liability as it adds two HBD and increases PSA),
good BBB permeation and Aβ reduction in cerebrospinal fluid (CSF) were observed for some
derivatives in vivo. More importantly, Hunt et al. demonstrated a
pharmacokinetic/pharmacodynamic (PK/PD) relationship between free drug concentrations in
the brain and Aβ-lowering in CSF in wild-type guinea pig and rat. Optimization of brain
exposure led to the discovery of the lead compound (R)-4 (BACE-1 IC50 = 48 nM) (Figure 3),
which significantly reduced CSF Aβ in wild-type rodents and in monkey.33
The group also incorporated a 7-tetrahydropyrane (7-THP) A-ring at the P2’ site of the chroman
scaffold, providing a series of 1,3,4,4a,10,10a-hexahydropyrano[4,3-b]chromanes.34 This
modification was envisaged to improve selectivity for BACE-1 versus CatD, due to differences
8
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
8
in their active sites. They explored three different WH (aminohydantoin, aminooxazolines, and
aminothiazolines) as Asp-binding moieties, as well as SB-guided substitutions at P3 and P2′ sites
to modulate potency, selectivity, efflux and permeability (Figure 4). The aminohydantoin moiety
led to the most potent analogues, but with higher efflux ratios and lower permeabilities than the
two alternative WH. These derivatives showed good enzymatic (10-40 nM) and cellular (5-44
nM) potencies, and were 10-to-420-fold more selective for BACE-1 than for CatD. Importantly,
despite the high efflux, 5 (Figure 4) had the best coverage ratio (free brain concentration/cell
IC50) of the various 7-THP chromans in mouse PK models. Furthermore, 5 significantly reduced
CSF Aβ1-40 in guinea pig, rat, and cynomolgus (58%, 53%, and 63%, respectively).
2,3,4,4a,10,10a-hexahydropyrano[3,2-b]chromane (8-THP chroman) derivatives showed an even
better overall profile (Figure 5).35 As noted above, the aminohydantoin Asp binding moiety
correlated with high efflux, despite being the most potent. The enzymatic (41-98 nM) and
cellular (37-140 nM) potencies, and CatD selectivity (430−>2200-fold) of the aminooxazoline
and aminothiazoline analogues were dramatically enhanced by methylation at the β-position of
the 8-THP chroman core. Further optimization of the P3 moiety led to aminooxazoline 6 (Figure
5), which progressed to rat PD studies. Although 6 still showed efflux liability (efflux ratio of
3.4) and had a 7-fold lower coverage ratio in rat than 5, it showed a significant improvement in
CSF Aβ1-40 reduction (69%).
Other aminooxazoline derivatives have recently been reported as BACE-1 inhibitors.36-39 The
aminooxazoline xanthene 7 (Figure 6) has good BACE-1 enzymatic (2 nM) and cellular (25 nM)
potency, as well as overall favorable properties. It showed robust CSF and brain Aβ-lowering
activity in a rat PD model, but QTc prolongation in cardiovascular models, which is consistent
with in vitro activity on the cardiac hERG potassium channel (hERG Ki = 0.66 μM).36 Indeed,
9
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
9
hERG inhibition has frequently been associated with BACE-1 inhibitors. In fact, there is
evidence that the increase in the pKa and lipophilicity, which is required for efficacious BACE-1
inhibitors, increases the chance of hERG inhibition.40 Hence, reducing these two parameters is a
common approach for reducing hERG affinity. However, it is known that decreasing the pKa of
the Asp-binding motif generally decreases BACE-1 potency, while introduction of polarity
increases PSA, which correlates with Pgp recognition. A balance of low Pgp efflux, hERG, and
BACE-1 potency was achieved by introducing polarity at the P2′ site of 7 and simultaneously
reducing the PSA of the P3 group.36 Introducing a fluorine in position 4 of the xanthene ring also
improved BACE-1 enzymatic and cellular potencies (5-10-fold).36 The enhanced BACE-1
potency within the series was attributed to a favorable hydrogen-bond interaction between the 4-
fluoro atom and NH Trp76 of BACE-1. Thus, introducing a nitrogen atom at the 3- or 4-position
of the xanthene core was investigated to similarly engage NH Trp76.37,38 This modification
boosted BACE-1 potency and reduced hERG binding affinity, but elevated the Pgp efflux ratio.
Optimizing the P3 and P2’ groups resulted in several compounds with improved in vitro
profiles.37,38
The development of 3-aza-4-fluoroxanthenes was also explored.39 These lead-optimization
approaches resulted in compounds with robust reductions in CSF and brain Aβ levels in a naïve
rat PD model. In particular, compounds 8, 9 (AMG-8718), 10, and 11 (Figure 6) had excellent in
vitro profiles (BACE-1 IC50 = 0.3, 0.7, 0.9, 0.3 nM, respectively; cell IC50 = 4, 4.4, 21.1, and 4
nM, respectively) and good in vivo PD responses in rats. These compounds exhibited modest
hERG activity (8, hERG Ki = 3.28 μM; 9-11, hERG Ki 10 μM), and significantly reduced
potential for QTc prolongation in cardiovascular safety models in dog (8, 9 and 11) and monkey
(10).36-39 10 and 11 also produced robust and sustained reductions in CSF and brain Aβ in a non-
10
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
10
human primate PD model. They showed low in vivo clearance and good oral bioavailability in
preclinical species.38,39 Unfortunately, 9’s drug development was discontinued due to toxicity
issues. It elicited retinal toxicity leading to thinning of the outer nuclear layer of the retina in a
one month rat toxicity study to support first-in-human trials.41 Although the origin of the toxicity
was not established, it was speculated it was likely an off-target effect related to inhibition of
other proteases. Mandal et al. recently reported on novel bicyclic iminopyrimidinones42 to
optimize the in vivo profile and address the off-target liabilities (cytochrome CYP3A4 and
hERG inhibition) of a previous series of fused pyrrolidine iminopyrimidinone represented by 12
(Figure 7).43 Starting from 12, the group improved the ancillary profile and CNS properties by
truncating the P3 cyano-phenyl group (to reduce lipophilicity and hERG inhibition) and
optimizing the fluoropyrimidine moiety binding in the S2′−S2″ region (to modulate BACE-1
affinity and address CYP3A4 inhibition). They subsequently optimized the P1 thienyl ring to
improve affinity and selectivity. This resulted in the 2,4-difluorophenyl analogue 13 (BACE-1 Ki
= 5 nM, cell IC50 = 14 nM) (Figure 7), which robustly lowered CSF and cortex Aβ40 in both rats
and monkeys.
Importantly, by occupying the S1 and S2′-S2″ subpockets, 13 has a molecular shape that is novel
among those S1-S3-binding BACE-1 inhibitors that can potently lower central Aβ in nonrodent
preclinical species.
2.2 Aminothiazines
The FB-derived aminothiazine 14 (LY2811376, Figure 8) developed by Eli Lilly showed well-
balanced PK profiles and reduced CSF Aβ levels in different animal species.44 It was also the
first molecule to demonstrate sustained brain Aβ reduction in healthy volunteers. However,
11
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
11
clinical trials were discontinued due to preclinical retinal toxicity, potentially related to the off-
target CatD inhibition.44
Compound 14 exhibited only modest BACE-1 inhibitory activity (IC50 = 0.24 μM). Therefore,
increasing potency was considered as one strategy for widening the therapeutic window with
respect to the observed toxicity. In this regard, by targeting the flap backbone of the BACE-1
active site, Wu et al. discovered the 6-dimethylisoxazole-substituted biaryl aminothiazine 15
(Figure 8), with 34-fold improved BACE-1 inhibitory activity (IC50 = 8 nM) over 14.45 Despite
its potency, 15 produced only modest in vivo activity in rodents, due to poor brain penetration
and metabolic instability mainly related to oxidation of the pyrimidine ring. Both hurdles were
overcome with the development of the pyrazine-carboxamide 16 (Figure 8). The pyrimidyl
moiety of 15 was replaced with a carboxamide, and the 5,6-diflurophenyl substituent in the S1
pocket was optimal in terms of activity and metabolic stability. Optimization of the amide side
chain in the S3 pocket resulted in 16, which exhibited potent BACE-1 inhibitory activity (IC50 =
0.7 nM), and robust brain Aβ reduction in rat dose-response studies.45 An alternative approach to
addressing 15’s two major issues was to develop S3-truncated heteroaryl substituted
aminothiazines.46 Pyrimidine truncation boosted brain penetration (by reducing MW and PSA)
and metabolic stability (by removing a metabolic soft spot). Compound 17 (Figure 8) showed
improved BBB permeability and, despite its moderate enzymatic activity (IC50 = 0.15 μM), it
demonstrated significant brain Aβ reduction in rodents. 17 was relatively stable in rat and mouse
liver microsomes, but unstable in human microsomes, due to oxidation of the methyl group(s) of
the isoxazole ring. 17’s metabolic stability was addressed by replacing the 6-dimethylisoxazole
ring with a pyrimidine ring. This led to 18 (Figure 8) with good brain permeation and metabolic
stability, and enhanced in vivo activity in rodents.
12
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
12
An alternative approach to widening 14’s therapeutic window was to improve BACE-1
selectivity versus CatD. In this respect, Butler et al. recently reported on a reductionist approach,
truncating 14 to just the necessary pharmacophore, then evaluating opportunities to improve
CatD selectivity using SB drug design, without impacting CNS penetration.47 The group
developed a series of aminothiazine-THP fused derivatives, carrying a small lateral chain to
engage an induced pocket (S2’) formed by movement of the protein flap. These derivatives were
efficiently selective, maintaining the desired PK profile, as exemplified by 19 (Figure 8). The
compounds displayed robust efficacy in lowering both peripheral and central Aβ loads in vivo in
mice and dog models. In addition, chronic treatment in aged PS1/APP mice decreased the
number and size of Aβ-derived plaques. Most importantly, a 2-week exploratory toxicology
study of 19 revealed no retinal toxicity.
Despite its excellent overall properties, 19's weak in vitro potency against BACE-1 (IC50 = 1.07
μM), meant a high human dose was projected ( 500mg/day), which prevented its further
investigation. A new generation of novel heterocycle-substituted analogues of 19 was designed
based on structural information. Particularly, as the fluoromethyl group of 19 was found to
suboptimally fill the S2’ pocket, it was postulated that positioning a heteroaryl substituent in this
pocket could improve potency, while maintaining the overall lipophilicity and alignment of
ADME properties. This led to potent, low-clearance, CNS-penetrating BACE-1 inhibitors,
represented by 20 in Figure 8 (BACE-1 IC50 = 52 nM, cell IC50 = 4n M).48 However, further in
vitro profiling with human recombinant CYPs showed that CYP2D6 significantly contributed to
20’s metabolism, causing drug-drug interaction (DDI) concerns.
SB-guided efforts to reduce 20’s cytochrome CYP2D6 metabolism issues resulted in highly
potent derivatives, with reduced risk for DDI, central efficacy, and improved hERG therapeutic
13
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
13
margins. In particular, due to their promising overall profiles, compounds 21 and 22 (Figure 8)
have advanced to long-term safety studies, with the results expected in due course.
As noted above, Eli Lilly discovered 1444 and, more recently, the furo[3,4-d][1,3]thiazin-2-amine
picolinamide LY2886721 (23 in Figure 9), a potent BACE-1 inhibitor that reached Phase 2
clinical trials to treat early AD.49 Ely Lilly researchers then used a FB approach to target
topologically complex polycyclic aminothiazines as BACE-1 inhibitors. Starting from the
millimolar bicyclic thiazine fragment hit 24 (Figure 10), identified in a high concentration
BACE-1 enzymatic assay, they obtained the FB-derived compounds 25 and 26 (Figure
10).50Compounds 25 and 26 showed poor potency in vitro (BACE-1 IC50 = 1.83 and 2.25 μM,
respectively) and in vivo (lack of Aβ brain reduction was consistent with low cerebral exposure).
However, key SAR hypotheses could be tested with these compounds. These tests revealed that
S3-binding could remarkably increase the potency of this series, but that conformational
constraint would not lead to further enhancements.
Bristol-Myers Squibb recently developed a novel series of more easily accessible furo[2,3-
d]thiazine isosteric analogues of 23, represented by 27 and 28 in Figure 9 (BACE-1 IC50 = 20
and 37 nM, respectively). 27 and 28 showed cellular activity comparable to that of the parent
compound 23 and good in vitro permeability. However, they demonstrated low exposure and
only modest reduction in Aβ brain levels in mice.51
2.3 Iminothiadiazinanes dioxide
Merck recently reported on the discovery and characterization of a novel iminothiadiazinane
dioxide class of BACE-1 inhibitors, represented by the advanced clinical compound 1 (Figure
1).11 Starting from the elaboration of initial isothiourea fragment screening hits,52 subsequent
14
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
14
search for heterocycle isothiourea isosteres, and extensive SAR exploration around the
iminothiadiazinane dioxide core, Merck developed the highly optimized inhibitor 1. Based on the
potent in vitro and vivo iminopyrimidinone BACE-1 inhibitor 29 (BACE-1 Ki = 1.7 nM),53 and
seeking to identify novel Asp-binding cores that could offer unexplored intellectual property
space, the iminothiadiazinane dioxide 30 (BACE-1 Ki = 2.4 nM) was developed (Figure 11).
Although 30 (cell IC50 = 55 nM) displayed weaker cellular potency than 29 (cell IC50 = 11 nM), it
was significantly more potent in vivo, probably due to the enhanced CNS penetration imparted
by the iminothiadiazinane dioxide core. In an acute rat PD assay, 30 afforded robust reductions
of CSF and cortex Aβ40 levels. Despite the favorable PD profiles, 29 and 30 were not developed
further due to metabolic issues and modest CatD selectivity (21- and 47-fold, respectively).
These two liabilities were overcome by SB optimization of the P3 and P1 binding motifs, leading
to the discovery of 1 (BACE-1 Ki = 2.2 nM). Compound 1 was highly selective for BACE-1
over other aspartyl proteases, with the exception of BACE-2, and potently inhibited Aβ
formation in cell-based assay (cell IC50 = 2.1 nM). Compound 1 showed a good PK/PD profile in
preclinical species, profoundly lowered CSF and brain Aβ levels after acute and chronic
administration to rats and monkeys, and was advanced to phase 1 clinical trial to assess safety,
PK and PD in healthy volunteers and mild to moderate AD patients.10 Single and multiple doses
were generally well tolerated and produced reductions in Aβ levels in the CSF of both healthy
human subjects and AD patients. In 2012, 1 entered into phase 2/3 clinical trial in people with
mild to moderate AD (EPOCH trial), and in 2013 a phase 3 trial for prodromal AD (APECS
trial) was also started. While EPOCH has been recently discontinued due to lack of efficacy,
APECS will continue to address the question of timing of intervention of BACE-1 inhibition in
AD (results are expected by February 2019).54
15
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
15
2.4 Iminohydantoins
Merck recently reported SB drug design efforts around the high-throughput screening hit,
spiropiperidine iminohydantoin 31 (BACE-1 IC50 = 22 μM, cell IC50 > 30 μM) (Figure 12).55
This led to compounds with more than 200-fold and 90-fold improved BACE-1 enzymatic and
cell-based potency, respectively. This remarkable achievement was made possible by adding a
strategically placed methyl group on the piperidine ring. This methyl group maintained the
required pKa of the N-piperidine nitrogen, filled a small hydrophobic pocket, and stabilized the
best conformation for optimized binding to the receptor.56 Importantly, derivative 32 (BACE-1
IC50 = 6 nM, cell IC50 = 63 nM) (Figure 12) also showed good selectivity versus CatD (IC50 =
16.3 μM), and Aβ reduction in CSF in mice and monkeys.
2.5 Aminoxazines
Rombouts et al. recently reported on novel 6-F-3-amino-1,4-oxazines for the development of
BACE-1 inhibitors with improved CNS permeability.57 Lead optimization efforts fine-tuned the
amidine pKa and BACE-1 primary activity, resulting in compound 33 (BACE-1 IC50 = 7.6 nM;
cell IC50 = 8.1 nM) (Figure 13). Compound 33 was orally bioavailable, centrally active, and
robustly lowered brain and CSF Aβ levels in mouse and dog models, respectively. However,
brain penetration still needs to be balanced against metabolic stability and cardiovascular safety
(i.e. hERG inhibition).
2.6 Aminoquinolines
16
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
16
The potent SB-designed aminoquinoline derivative 34 (BACE-1 IC50 = 0.8 nM) was recently
developed by linking the known BACE-1 inhibitor 35 (BACE-1 Kd = 140 nM)58 with the S3
binding fragment 36, identified in a 19F-NMR second-site fragment screen (Figure 14).59
Compound 34 exhibited a 350-fold increase in BACE-1 affinity, while maintaining reasonable
ligand efficiency and gaining much improved selectivity over CatD with respect to the parent
compound 35.
2.7 Macrocyclic acyl guanidines
The acyl guanidine chemotype is well-known in BACE-1 inhibitor development. Boy et al
recently reported on a macrocyclization strategy to improve the in vitro potency and Pgp liability
of parent acyclic acyl guanidine inhibitors.60 Compound 37 (Figure 15) showed good in vitro
potency (BACE-1 Ki = 3.2 nM, Cell IC50 = 140 nM), with robust peripheral Aβ-reduction in a
wild-type mice model. However, further effort is still required to lower Pgp efflux and enhance
CNS penetration, thereby achieving meaningful central exposure.
2.8 Miscellaneous
Recently reported in silico studies have led to the identification of new series of 4-oxo-1,4-
dihydro-quinoline-3-carboxamides,61 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-
dihydropyridines,62 allylidene hydrazinecarboximidamides,63 sulfonyl-amino-acetamides,64 and
(3S,4S)-4-aminopyrrolidine-3-ols65 with micromolar BACE-1 inhibitory activity. These can be
considered as suitable starting points for further investigation.
3. SB approaches to discovering BACE-1 inhibitors
17
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
17
BACE-1 has been extensively characterized at the structural level. The enzyme presents three
peculiar features that should be taken into account during drug discovery. First, the BACE-1
binding site is very extended (roughly 1000 Å3 in size) and displays an elongated shape over 20
Å in length along the main axis.66 Usually, this pocket is conveniently described as a collection
of sub-sites, which display varying physico-chemical local environments. Recently, a
combination of docking studies and molecular dynamics (MD) simulations was used to
investigate the selectivity of four BACE-1 inhibitors with respect to closely related proteases
(BACE-2 and CatD).67 Simulations showed that these compounds were too bulky to fit in the
comparatively narrow binding pocket of BACE-2 and, conversely, could not establish stable
interactions within the wider pocket of CatD.
Flexibility is the second relevant feature to consider when designing BACE-1 inhibitors. The
BACE-1 binding pocket is very flexible, as flexibility is instrumental to catalysis, and induced-fit
effects are to be expected. As of today, querying the Protein Data Bank for the human BACE-1
UniProt Accession ID (P56817) returns 355 unique hits.68 Possibly due to the abundance of
crystal structures combined with its pharmacological relevance, BACE-1 is considered an ideal
case study for investigating the role of receptor flexibility in docking and virtual screening.69-71
Cosconati and colleagues implemented an advanced ensemble docking strategy relying upon an
energy-weighted set of descriptors averaged over multiple conformations of BACE-1.72 Their
method identified novel chemotypes displaying BACE-1 inhibitory activity in a prospective
virtual screening campaign. Selected examples 38-40 are reported in Figure 16.
The third relevant structural element is the enzyme’s catalytic machinery: the aspartic dyad
formed by Asp32 and Asp228 and located at the center of the binding site. Since contacting the
dyad is fundamental for inhibitory activity, several studies have attempted to identify the
18
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
18
protonation state of the aspartic acid residues conducive to tighter interactions.73,74 Ligands
interacting with the aspartic dyad by means of chemically different groups preferentially interact
with different protonation states. Different protonation states alter the local electrostatic
environment and differently positioned hydrogen atoms in neutral side chains alter hydrogen
bond networks. A mismatch between a certain chemotype and the dyad titration state can
compromise the reliability of ligand affinity predictions. Barman and Prabhakar systematically
investigated the effect of eight rearrangements of the dyad in self-docking simulations carried
out on eight diverse ligands.75 For each chemotype, they identified a protonation state that
returned the best results in terms of reproducing the native pose and the binding energy. Even
when the bound conformation was reproduced by multiple dyad rearrangements, one often
emerged as the most favorable. This confirmed the existence of a clear link between dyad
protonation and ligand bound conformation. Dominguez and colleagues further extended the idea
of improving docking accuracy by modulating dyad protonation, extending pKa calculations to
all titratable residues in the BACE-1 binding site.76 Their results showed a small but significant
improvement with respect to protocols where side chains are assigned default states. Bottegoni et
al. considered five protonation states for the dyad in a virtual screening protocol, which was
purposefully designed to identify multitarget fragments endowed with activity at BACE-1 and
the glycogen synthase kinase 3GSK-3, another known target for AD treatment).77 Fragment-
dyad protonation binding scores were systematically evaluated and each compound was assigned
the best generated score. Interestingly, the only fragment endowed with dual activity at both
targets, 41 (Figure 16) preferentially interacted at the BACE-1 variant displaying a di-
deprotonated dyad.
19
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
19
In the above studies, protein flexibility and dyad protonation were considered almost
independent issues. In Kacker et al., we combined docking, quantum-mechanical (QM)
calculations, and MD to investigate the roles played by dyad protonation and protein flexibility
in order to identify novel BACE-1 inhibitors by virtual ligand screening.78 Our results
demonstrated that the two variables had to be considered together in order to obtain significant
enrichment in terms of the number of active compounds and their chemical diversity. This may
explain why, until recently, computational methods, which focused on only one of these two
aspects at a time, did not play a pivotal role in BACE-1 inhibitor identification.79 Indeed, MD is a
technique whose role in drug discovery has been steadily growing in recent years. Since the
pioneering work of Park and Lee, MD has been used, either by itself or in combination with QM
techniques, to investigate dyad protonation.80 More recently, constant pH MD (CpHMD)
simulations produced relevant insights into the crosstalk between protonation states and protein
conformations. The original CpHMD implementation includes pH as an additional
thermodynamic term in classic MD.81 Changes in the protonation state of titratable residues were
introduced along the trajectory by a Metropolis Monte Carlo (MMC) procedure. CpHMD can be
embedded within a replica exchange framework, allowing the exchange of pH between adjacent
replicas.82,83 This significantly improves sampling, generating much more efficiently a converged
thermodynamic ensemble in both conformational and protonation spaces. Constant pH replica
exchange MD (pH-REMD) was used to elucidate, at the molecular level, the role of pH in
substrate and inhibitor binding.84 BACE-1 exists in multiple conformational states. At its
working pH (between 2.5 and 4.5), the catalytically active conformation is the most populated.
Values of pH outside this range shift the thermodynamics equilibrium toward self-inhibited, non-
catalytically competent conformers. In another study, Kim and colleagues used constant pH-
20
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
20
REMD to calculate pH-dependent binding free-energy profiles associated with selected BACE-1
inhibitors.85 They reported how free-energy-calculation errors exceeding 8 kcal/mol can be
caused by incorrectly assigning the protonation state of both the catalytic dyad and other
titratable residues surrounding the catalytic machinery. Constant pH-REMD was also used to
retrospectively explain a puzzling affinity difference between two structurally related BACE-1
inhibitors.86 Even relatively high-resolution crystallographic structures of the bound complexes
could not account for the difference in potency, since the two molecules interacted with the
enzyme with comparable orientations and contacting the same residues. Simulations explained
how, at BACE-1’s working pH range, the structural differences between these compounds, while
very subtle, were still pronounced enough to stabilize different protonation states in the dyad,
altering the surrounding H-bond pattern and ultimately accounting for the different potency.
In more advanced stages of drug discovery, the research focus shifts from identifying novel
compounds to optimizing the identified hits. BACE-1 inhibitors have been successfully
investigated using protocols that estimate the relative binding free-energy variation associated
with a structural modification of a molecule.87 The idea is to explore the chemical space around
an interesting scaffold to identify those substituents which lead to improved affinity or, more
generally, a better pharmacological profile. At this stage, using these more computationally
demanding methods is acceptable because, on average, there are fewer molecules to investigate.
Ciordia and colleagues used free-energy perturbation (FEP) to investigate a series of amidine-
containing spirocyclic BACE-1 inhibitors.88 Targeting specific subpockets at BACE-1 binding
site, they first calibrated the FEP procedure on retrospective data to identify the best trade-off
between sampling thoroughness and correlation with experimental values of the simulation
output. The authors emphasized the importance of accomplishing such calculations within an
21
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
21
acceptable timeframe for a drug discovery campaign, particularly in an industrial setting. They
then applied the tuned protocol to predict new compounds. After synthesis and biological
evaluation, the predicted potencies for the synthesized spiroaminodihydropyrroles (exemplified
by 42 in Figure 16) were in fairly good agreement with the experimental results. In addition to
computational time, FEP calculations are also limited because reliable predictions cannot be
achieved for more radical modifications. To overcome this, Keränen and colleagues recently
reported a “Core Hopping FEP+” approach that was successfully applied to a series of
acylguanidine-bearing BACE-1 inhibitors (exemplified by compound 43 in Figure 16).89
Comparing the computational outcome with experimental results, the match was very accurate
for local substitutions and, while slightly less accurate, still encouraging when more radical
scaffold modifications were attempted. Interestingly, when investigating the effect of sampling
in obtaining converged calculations, multiple short runs returned more accurate results than a
single, more extended trajectory.
In summary, while success stories have been episodically described and several new hit
compounds have been reported, the prospective application of computer-assisted drug discovery
methods to BACE-1 remains challenging. This multifaceted target severely limits the reliability
of standard computational hit-discovery and optimization protocols. In line with a general and
widespread trend in drug discovery,87,90-92 more complex and time-consuming methods based on
MD, QM, and enhanced sampling approaches,90so far applied in an almost exclusively
retrospective fashion, will play an increasingly important role in the prospective development of
new BACE-1 inhibitors.
4. Multitarget compounds centered on BACE-1
22
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
22
MTDLs are (usually) small organic molecules that can simultaneously modulate more than one
target. They are gaining increasing attention from the medicinal chemistry community because
they can show superior therapeutic profiles relative to conventional single-target molecules,
particularly for treating complex and multifactorial diseases, including neurological disorders.
Indeed treating Alzheimer’s, Parkinson’s, and other neurodegenerative diseases has been one of
the major focuses of multitarget drug discovery strategies in the last twenty years.24 From
Melchiorre et al’s pioneering study93 through to recent MTDLs that interfere with AD’s amyloid
and tau cascades,94-96 many papers have hypothesized that innovative multitarget strategies could
address the complexity of neurodegenerative diseases, which remain a huge unmet medical need
worldwide. However, none of these compounds has progressed beyond the preclinical phase,
demonstrating that MTDLs create a big challenge in terms of both discovery and development.
BACE-1 is a rather difficult target for SB design, mainly because the site is quite solvent-
exposed. This requires a good compromise between hydrophobic and hydrophilic moieties in
order to achieve good affinity, good residence time, and an appropriate PK profile. Additionally,
experimental evidence has shown that different functional groups present on diverse BACE-1
inhibitors can stabilize the dyad in different protonation states, thus altering the dyad’s overall
charge. This makes SB design of BACE-1 binders even more challenging.78 In terms of
designing BACE-1-based MTDLs, it can be very demanding to identify small molecules that can
inhibit BACE-1 in combination with a second (or a third) target. Indeed, it is not easy to design
and optimize small molecules for two targets that are often unrelated, genetically and
biologically. Furthermore, it is well known that pharmacokinetics has been quite an issue in
BACE-1 inhibitor field,17 further challenging the discovery of multitarget compounds centered
on BACE-1. Finally, from the in vivo evaluation standpoint, usually multitarget compounds can
23
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
23
be particularly complex to investigate, and systematic experimental protocols have to be defined
to properly profile them, also in terms of comparison with drug combinations. For these reasons,
the literature contains just a few reports of MTDLs centered on BACE-1, and these molecules
have mainly been evaluated in vitro by means of biochemical and cell-based experiments. Here,
we review and discuss these examples from the medicinal chemistry perspective. We first
consider dual-target inhibitors modulating BACE-1 and another AD-related target. Then, we
discuss multitarget compounds where more than two targets are simultaneously hit. We will
discuss molecules that inhibit BACE-1 and have other “general” and often target-unrelated
mechanisms, such as antioxidation, radical scavenging, and metal chelation.
A comment is eventually required on the scaffold selection in multitarget drug discovery, as
many compounds can show multiple mechanisms of action in vitro, mainly because of the
promiscuity and wide reactivity of the chemical groups they carry. In these circumstances, there
exist the actual risk that such multitarget compounds are simply promiscuous molecules,
sometimes resulting in pan-assay interference compounds (PAINS) rather than in clean and
rationally designed multitarget compounds.97 This issue should be carefully considered in
polypharmacology-based drug discovery and well-established protocols should be devised to
properly design, discover, and develop multitarget molecules. This aspect is even more relevant
for CNS-directed candidates, as the lead optimization phase should comply with a suitable drug
metabolism and PK profile for CNS, while preserving affinity towards two or more targets.
4.1 Dual BACE-1/acetylcholinesterase (AChE) inhibitors
The acetylcholinesterase (AChE) enzyme was the first target within the cholinergic hypothesis to
be extensively investigated in the search for novel AD drug candidates. Anti-AChE compounds
24
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
24
are still the only drugs approved for treating AD. Despite their limited efficacy, they can
alleviate symptoms in the early symptomatic phase of the disease.98 From a multitarget drug
discovery standpoint, it was rather obvious that the pharmacophoric functions responsible for
AChE inhibition might be combined with functional groups thought to interact with BACE-1. In
2008, Piazzi et al. reported a novel series of coumarin-derivatives that were potent and balanced
dual BACE-1/AChE inhibitors.99 These compounds were derived from AP2238 (44 in Figure
17), one of the first ever AChE inhibitors that was rationally designed to bind both the internal
and peripheral anionic sites of AChE.100 This peculiar feature allowed 44 to also interfere with
AChE-induced A aggregation, making it an MTDL with a rather unique mechanism of action.
Starting from pharmacophore 44, Piazzi et al. substituted one of its two methoxy groups with a
halophenylalkylamidic group, obtaining rather large compounds endowed with a dual
mechanism of action. Indeed, the potency against AChE was fairly well-preserved, while gaining
activity against BACE-1. In particular, 45 (Figure 17) showed a fairly balanced biological profile
against the two targets, with an IC50 of about 181 nM against AChE and 150 nM against BACE-
1.
In 2014, seeking to identify a novel class of dual BACE-1/AChE inhibitors, the same group
screened an internal library of benzophenone derivatives, with promising AChE-inhibiting
profiles, for activity against BACE-1.101 Most of these compounds were inactive. However, a
couple showed single-digit micromolar activity against BACE-1, but with a remarkably reduced
potency against AChE. This example demonstrates that discovering and, more importantly,
optimizing MTDLs is likely one of the biggest challenges in multitarget drug discovery. Indeed,
optimizing hits against one target often significantly reduces potency against the other(s). This
makes MTDL lead optimization a rather complicated and often frustrating process. Similarly, in
25
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
25
2015, Rampa et al. reported a series of compounds based on the indanone structure, where
chemical modifications on the common core could switch from BACE-1 to AChE inhibition and
vice versa. This further demonstrates the complexity of optimizing dual-target compounds
against such ancestrally divergent biological targets.102
Following the hybrid approach, Zha et al. very recently designed, synthesized, and biologically
evaluated more than 20 tacrine-benzofuran compounds as dual inhibitors. Of these, 46 (Figure
17) showed subnanomolar potency against AChE and single-digit micromolar inhibition against
BACE-1, further highlighting the complexity of balancing the biological profiles of multitarget
inhibitors.103
In the same year, Costanzo et al. published a promising study involving a series of donepezil-
derivatives as dual AChE/BACE-1 inhibitors. In addition to reporting a sustainable multistep
protocol for synthesizing a set of donepezil derivatives, the authors tested the new molecules for
selectivity against AChE (versus BuChE). Given donepezil’s mild activity against BACE-1, they
also tested these molecules for BACE-1 inhibition. Compound 47 (Figure 17) was slightly less
potent than the parent compound against AChE (Ki = 29 nM versus 10 nM of donepezil), with a
promising inhibiting profile against BACE-1 (less than 20% of residual enzymatic activity at 1
M concentration). This compound could indeed be a promising candidate for developing
AChE/BACE-1 multitarget inhibitors to treat AD.104
In 2009, Zhu et al. used a slightly different strategy to rationally design a series of
BACE-1/AChE inhibitors. In particular, they rationally combined moieties responsible for AChE
inhibition with those able to modulate BACE-1. This led to three series of derivatives with a
dual-target mechanism of action.105 Reviewing all the data published by the authors, it is
interesting to note that most of the compounds showed single-target activity, and that slight
26
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
26
chemical modifications allowed them to switch from pure AChE inhibitors to pure BACE-1
inhibitors, with a few genuine dual-target compounds. Fine-tuning the single-target and dual-
target activities can deepen our understanding of the SARs for each compound class. This should
allow a more rational and accurate engineering of next-generation BACE-1/AChE dual-target
inhibitors.
For the final examples of dual BACE-1/AChE inhibitors, we mention two studies where the
authors obtained compounds with rather complex mechanisms of action. These molecules
modulated BACE-1, AChE, and additional targets. In 2009, Camps et al. designed and
discovered a series of quinoline-chlorotacrine hybrids with a rather complex biological profile.
These molecules inhibited AChE, by binding at the enzyme’s internal and peripheral anionic
sites.106 As such, these hybrid compounds also counteracted the AChE-induced A aggregation.
Surprisingly, they also inhibited BACE-1. In particular, compound 48 (Figure 17) was about 14
nM against AChE and also blocked almost 80% of BACE-1 activity at 2.5 µM concentration,
pointing to an IC50 in the submicromolar range. In addition, 48 inhibited both AChE-induced and
spontaneous A aggregation in the high micromolar range. Overall, its complex biological
profile suggested 48 as a promising MTDL, acting at different key points in complementary
neurodegenerative cascades of AD. Additionally, this compound crossed the BBB, despite its
large size and rather high MW.
In 2011, Huang et al. designed and discovered a series of quinoxaline derivatives, which also
showed a complex multitarget biological profile.107 These compounds showed BACE-1
inhibition and/or AChE inhibition. Some were also histamine H3 receptor antagonists. The
cholinergic hypothesis provides the rationale for this additional biological activity. Blocking this
presynaptic receptor can increase ACh levels in the synaptic cleft via a different mechanism than
27
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
27
classical AChE inhibition. The activated presynaptic histamine H3 receptor decreases the release
of ACh from cholinergic neurons. Antagonists of this receptor can thus increase ACh levels,
likely producing a synergistic effect for treating AD. Of the 17 quinoxaline analogues in the
series, most showed activity against one or two targets. Only one compound (49 in Figure 17)
modulated (i.e. inhibited and antagonized) all three selected targets. Similarly, Viayna et al.
recently reported a new series of rhein-huprine hybrids with a rather complex pharmacological
profile, being AChE/BACE-1 dual inhibitors and dual antiaggregating compounds for Aβ42 and
tau.108
This further highlights the complexity of discovering, optimizing, and developing MTDLs.
Pragmatically speaking, we envisage that a well-designed MTDL drug discovery program will
involve the rational and accurate selection of two targets, whose modulation provides a true
synergistic effect against a given disease. This effect can be pharmacologically demonstrated at
an early stage by using selective binders of the two selected targets. Then, the chemical design
step should be conducted very carefully to allow modifications on the identified scaffold(s) that
are not detrimental for either target. SB approaches could be remarkably helpful in these very
early steps. A clear understanding of the SARs could help in rationally selecting modifications to
achieve balanced MTDL lead candidates. There should be sufficient room (in terms of chemical
tractability, size, and MW) for lead optimization, so that pharmacokinetics and toxicology
profiles can be carefully considered, and chemical modifications made to improve the profile of
the new compounds without losing affinity for either target. FB drug discovery would be
particularly appropriate here. This is because fragments can intrinsically be endowed with a
polypharmacological mechanism of action, and because there is more room for chemical
modifications on fragments than on larger lead-like compounds.
28
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
28
A comment is here required on the possible clinical utility of dual AChE/BACE-1 inhibitors in
AD. Actually, the lack of efficacy of 1 in mild-to-moderate AD suggests that it is too late in the
disease process for BACE-1 inhibition to be effective. Conversely, this patient cohort could be
symptomatically treated with AChE inhibitors, despite the well-known moderate efficacy of
these inhibitors in the clinical practice. Indeed, the two targets can play a role in two well-
separated phases of the disease progression. We may therefore be confronted with a scenario
where a dual AChE/BACE-1 could lead to a rather superfluous anticholinesterase activity in
prodromal AD patients, and to a clinically useless inhibition of BACE-1 in mild-to-moderate AD
patients. The two drugs could conversely be used separately in different phases of the disease,
with clear different mechanisms of action tackling different pathological pathways in the AD
progression. The most recent clinical trials have greatly helped in better detangling the role of
different pathways and molecular mechanisms in the disease progression and therapeutic
treatments.
4.2 Dual BACE-1/GSK-3 inhibitors
While BACE-1 is one of the key enzymes within the amyloid cascade, GSK-3 is one of the
kinases responsible for phosphorylation of the tau protein, which then detaches from
microtubules to form neurofibrillary tangles. This is AD’s second key histopathological
hallmark. Indeed, one strategy for treating AD could be inhibiting both enzymes, possibly
producing a downstream synergistic effect. With this in mind, we recently discovered and
developed a class of fragments bearing a triazinone skeleton as dual BACE-1/GSK-3
inhibitors.94,95 In detail, exploiting a ligand-based approach, we combined the pharmacophoric
functions responsible for binding to the enzymes. These were i) the cyclic amide group that binds
29
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
29
to kinases, and ii) the guanidine moiety that, when positively charged, binds to the aspartic dyad
of BACE-1. Merging these functional groups led to a series of triazinone derivatives with a
balanced micromolar affinity for the two targets. Most of the new derivatives had a very low
MW. This prompted us to assess the pharmacokinetic profile of one selected compound.
Compound 50 (Figure 18) showed good bioavailability (66%) upon oral administration in mice,
and good BBB penetration. Indeed, at the very low dose of 3 mg/kg, 50 showed a brain
concentration of 0.62 M after 30 minutes. Although below the in vivo target engagement levels,
this represents an attractive starting point towards a promising lead optimization campaign.
Interestingly, cellular data showed that this multitarget compound class also had anti-
neuroinflammatory and neurogenic effects. This may have been due to GSK-3 modulation or
the simultaneous inhibition of both targets. Subsequent in vivo data will ultimately demonstrate
whether the molecule’s profile makes it suitable for progression through the drug discovery and
development pipelines.
Taking a different approach to dual BACE-1/GSK-3 inhibitors, Di Martino et al. developed
MTDLs by exploiting the versatility of the natural compound, curcumin.96 Using a SB approach
to modify this privileged molecule, suitable moieties were mounted onto the curcumin
framework to confer the new molecules with the ability to bind to both enzymes. The series of
curcumin derivatives was fairly potent against BACE-1 and GSK-3but, for most derivatives,
the two actions were not properly balanced. For example, 51 (Figure 19) showed nanomolar
inhibition of BACE-1, but single-digit micromolar inhibition of GSK-3.
Interestingly, some of these compounds induced the NAD(P)H:quinone oxidoreductase 1
(NQO1). This enzyme is responsible for the endogenous conversion of quinones to
hydroquinones. By counteracting the oxidative stress that is a common feature of AD, this could
30
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
30
translate to a potential neuroprotective effect. Indeed, a recent longitudinal study demonstrated
that air pollution from traffic could be an important risk factor for vascular dementia and AD.109
Exposure to air pollution can lead to chronic oxidative stress, which is a risk factor in the
pathogenesis of AD.110 NQO1 could thus be an intrinsic detoxifying and antioxidant weapon for
tackling oxidative stress. Molecules that can induce this enzyme are potential antioxidant drug
candidates for AD treatment. This intriguing mechanism was originally reported by some of us
in 2007, when investigating the polypharmacological profile of memoquin.111 In particular, we
demonstrated that the antioxidant effect of this quinone-bearing compound was due to the
hydroquinone species, which could be obtained through the enzymatic activity of NQO1 in vivo.
This concept was confirmed and extended in a subsequent study of memoquin in vivo. We
showed that sulphorafane, a potent natural inducer of NQO1, significantly increased the
antioxidant and neuroprotective effects of memoquin and other quinone-bearing compounds.112
According to the “mitochondrial dysfunction hypothesis” in AD, exploiting this detoxifying and
antioxidant mechanism could be one innovative strategy for tackling AD’s pathophysiology. The
curcumin-based derivatives developed by Di Martino et al. were therefore endowed with a rather
complex polypharmacological profile thanks to their dual inhibition of BACE-1 and GSK-3 and
their positive antioxidant effect as inducers of the NQO1 enzyme. It should however here be
mentioned that curcumin, as well as other natural compounds, could be endowed with a highly
promiscuous profile,97,113,114 and therefore further experimental evidences should be collected to
clearly demonstrate that such compounds specifically modulate the intended targets, rather than
showing a PAINS-like profile.
In conclusion, the papers by Prati et al. and Di Martino et al. point the way to a systematic
development of dual BACE-1/ GSK-3 inhibitors. These two key enzymes are involved in AD’s
31
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
31
two major pathological cascades (amyloid and tau) of AD. The resulting dual inhibitors may be
endowed with pharmacological profiles that are superior to those of classic single-target
molecules.
5. Conclusions and perspectives
While submitting this paper, we learned about compound 1’s lack of efficacy in mild-to-
moderate AD.115 Thus, we are again faced with profound questions concerning the amyloid
hypothesis along with the timing of BACE-1 inhibition, which remains one of the critical points
for properly developing novel drug candidates based on this hypothesis. We are forced to ask
ourselves: should we continue to develop BACE-1 inhibitors? Will it be worth the time, effort,
and cost? How large is the impact of the proper patient stratification and the clinical trial design?
It barely seems logical to persist in developing molecules that inevitably fail. Indeed, these
questions will probably find answers in the still ongoing phase 3 clinical development of 1 in
prodromal AD.
At this point, there is obvious appeal in the view that AD scientists in academia and industry
should learn from failures, both their own and those of others. Thus, a more appropriate question
may be: what have we, as a community, learned in the last 20 years of discovering and
optimizing BACE-1 inhibitors?
First, nowadays we know how to merge the structural requirements for potency and protease
selectivity with the strict need for BBB permeation, oral bioavailability, low metabolic clearance,
and tolerable toxicity.
Second, we have corroborated the power of FB approaches in CNS drug discovery: the case of 1
nicely exemplifies how an NMR screen can provide a weak fragment-hit that can be further
optimized into a nanomolar protease inhibitor. Other examples have since followed.10,11,94,95
32
705
706
707
708709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
32
Third, we have successfully incorporated the concepts of personalized medicine into drug
discovery and clinical trials. In the future, this could streamline the drug development process
and enable targeted therapies (once developed) to be delivered appropriately. In this respect, we
expect very interesting data to be produced by testing BACE-1 inhibitors in early-onset familial
AD patients. Indeed, they may be the ideal stratified patient population who will benefit most
from a “pure” anti-amyloid therapy. From this rational stratification, we could then perhaps
better understand whether BACE-1 inhibitors could be useful for non-familial AD patients.
Fourth, we have been reminded again of something that we already knew:24 the unfathomable
complexity of AD. Perhaps, the amyloid hypothesis is not sufficient to explain this intricate
multifactorial pathogenesis of AD. A feasible solution may thus be afforded by a well-designed
MTDL that can synergistically inhibit BACE-1 and modulate a second interrelated AD target.
The examples discussed herein point to the power of this approach and highlight the still-
undiscovered potential and the complexity of such molecules in AD drug discovery and
development.
AUTHOR INFORMATION
Corresponding Author
*E-mail: [email protected]
Author Contributions
The manuscript was written with contributions from all authors. All authors have approved the
final version of the manuscript.
ACKNOWLEDGMENT
33
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
33
We thank the University of Bologna and the Italian Institute of Technology for financial support.
We thank Grace Fox for copyediting and proofreading.
ABBREVIATIONS
CatD, cathepsin D; CpHMD, constant pH molecular dynamics; FB, fragment-based; FEP, free-
energy perturbation; GSK-3glycogen synthase kinase 3 MMC, Metropolis Monte Carlo;
MTDLs, multitarget-directed ligands; NQO1, NAD(P)H:quinone oxidoreductase 1; pH-REMD,
pH replica exchange molecular dynamics; PPIs, protein-protein interactions; QM, quantum-
mechanical; SB, structure-based; 7-THP, 7-tetrahydropyrane; 8-THP, 8-tetrahydropyrane; WH,
warhead.
BIOGRAPHIES:
Federica Prati received her Master’s degree in Chemistry and Pharmaceutical Technologies
from the University of Bologna in 2010. In 2013, she was a Visiting Scholar at the University of
Dundee Drug Discovery Unit (DDU), and in 2014 she was awarded the Ph.D. in drug discovery
from the University of Genova, in collaboration with the Istituto Italiano di Tecnologia
(Genova). She is presently working as Open Lab-Marie Curie fellow at the Tres Cantos
medicines development campus in GlaxoSmithKline, in close partnership with the DDU of
Dundee.
Her research interests focus on medicinal chemistry and drug discovery. Particularly, she
contributed to the development of small active molecules, through fragment-based and multi-
target approaches, against cancer, tuberculosis, neurodegenerative and neglected tropical
diseases.
34
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
34
Giovanni Bottegoni is a scientist and an entrepreneur. He holds a Ph.D. in pharmaceutical
sciences (University of Bologna, Italy, 2006) and a master in healthcare management (SDA
Bocconi, Italy, 2014). For two years, he was post-doc at The Scripps Research Institute in La
Jolla, California (USA), and then he joined the Istituto Italiano di Tecnologia (Genova, Italy)
first as a post-doc and later as a team leader. In 2014, he co-founded BiKi Technologies, a start-
up company that commercializes software solutions for medicinal chemistry and, for two years,
was CEO of the company. He currently works as a senior scientist for Heptares Therapeutics
(Welwyn Garden City, UK). He is the author of over 50 publications and co-inventor in several
patents. In 2015, he was awarded the DCF prize for medicinal chemistry by the medicinal
chemistry division of the Italian chemical society.
Maria Laura Bolognesi is Professor of Medicinal Chemistry and Director of the Chemistry and
Pharmaceutical Technologies degree program at the University of Bologna. Her research spans
the design, synthesis and pharmacological investigation of small molecules in the
neurodegenerative and neglected tropical disease therapeutic areas. She has a track record of
more than 140 publications in high-ranked scientific journals, including patents and patent
applications, and more than 50 invited talks worldwide. She was awarded a Distinguished
Visiting Professor Fellowship at the Complutense University of Madrid in 2009, and a PVE
Fellowship at the University of Brasilia in 2014. She is also an Associate Editor of Journal of
Medicinal Chemistry.
Andrea Cavalli is Professor of Medicinal Chemistry at the University of Bologna and Research
Director at the Istituto Italiano di Tecnologia, where he is also Deputy Director for Computation
35
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
35
& Data Science. His research interests are in the field of computational drug discovery. In
particular, he has developed and applied computational approaches to accelerate the discovery of
drug-like compounds in several therapeutic areas, including cancer, neurodegenerative diseases,
and neglected tropical diseases. Prof. Cavalli is the author of more than 200 publications in high-
ranked journals, inventor of several PCT international patents, and has delivered numerous
invited lectures and seminars. In 2003, he was awarded the “Farmindustria Prize for
Pharmaceutical Research”. He is co-founder of the high-tech startup company, BiKi
Technologies.
REFERENCES
1. Hardy, J. A.; Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis.
Science 1992, 256, 184-185.
2. Morris, G. P.; Clark, I. A.; Vissel, B. Inconsistencies and controversies surrounding the
amyloid hypothesis of Alzheimer's disease. Acta Neuropathol. Commun. 2014, 2, 135.
3. Herrup, K. The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci. 2015,
18, 794-799.
4. Kepp, K. P. Ten challenges of the amyloid hypothesis of Alzheimer's disease. J.
Alzheimer's Dis. 2017, 55, 447-457.
5. Lemere, C. A. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol.
Neurodegener. 2013, 8, 36.
6. Karran, E.; Hardy, J. A critique of the drug discovery and phase 3 clinical programs
targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 2014, 76, 185-205.
7. http://www.alzforum.org/therapeutics/jnj-54861911 (June 7, 2017).
36
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
36
8. http://www.alzforum.org/therapeutics/cnp520. (June 7, 2017).
9. http://www.alzforum.org/therapeutics/ly3202626-0 (June 7, 2017).
10. Kennedy, M. E.; Stamford, A. W.; Chen, X.; Cox, K.; Cumming, J. N.; Dockendorf, M.
F.; Egan, M.; Ereshefsky, L.; Hodgson, R. A.; Hyde, L. A.; Jhee, S.; Kleijn, H. J.; Kuvelkar, R.;
Li, W.; Mattson, B. A.; Mei, H.; Palcza, J.; Scott, J. D.; Tanen, M.; Troyer, M. D.; Tseng, J. L.;
Stone, J. A.; Parker, E. M.; Forman, M. S. The BACE1 inhibitor verubecestat (MK-8931)
reduces CNS beta-amyloid in animal models and in Alzheimer's disease patients. Sci. Transl.
Med. 2016, 8, 363ra150.
11. Scott, J. D.; Li, S. W.; Brunskill, A. P.; Chen, X.; Cox, K.; Cumming, J. N.; Forman, M.;
Gilbert, E. J.; Hodgson, R. A.; Hyde, L. A.; Jiang, Q.; Iserloh, U.; Kazakevich, I.; Kuvelkar, R.;
Mei, H.; Meredith, J.; Misiaszek, J.; Orth, P.; Rossiter, L. M.; Slater, M.; Stone, J.; Strickland, C.
O.; Voigt, J. H.; Wang, G.; Wang, H.; Wu, Y.; Greenlee, W. J.; Parker, E. M.; Kennedy, M. E.;
Stamford, A. W. Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative
verubecestat (MK-8931)-Abeta-site smyloid precursor protein cleaving enzyme 1 inhibitor for
the treatment of Alzheimer's disease. J. Med. Chem. 2016, 59, 10435-10450.
12. Nie, Q.; Du, X. G.; Geng, M. Y. Small molecule inhibitors of amyloid beta peptide
aggregation as a potential therapeutic strategy for Alzheimer's disease. Acta Pharmacol. Sin.
2011, 32, 545-551.
13. McKerrow, J. H.; Rosenthal, P. J.; Swenerton, R.; Doyle, P. Development of protease
inhibitors for protozoan infections. Curr. Opin. Infect. Dis. 2008, 21, 668-672.
14. Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A. K.; Zhang, X. C.; Tang, J.
Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor.
Science 2000, 290, 150-153.
37
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
37
15. Ghosh, A. K.; Brindisi, M.; Tang, J. Developing beta-secretase inhibitors for treatment of
Alzheimer's disease. J. Neurochem. 2012, 120 Suppl 1, 71-83.
16. Ghosh, A. K.; Osswald, H. L. BACE1 (beta-secretase) inhibitors for the treatment of
Alzheimer's disease. Chem. Soc. Rev. 2014, 43, 6765-6813.
17. Yuan, J.; Venkatraman, S.; Zheng, Y.; McKeever, B. M.; Dillard, L. W.; Singh, S. B.
Structure-based design of beta-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment
of Alzheimer's disease. J. Med. Chem. 2013, 56, 4156-4180.
18. Butini, S.; Brogi, S.; Novellino, E.; Campiani, G.; Ghosh, A. K.; Brindisi, M.; Gemma, S.
The structural evolution of beta-secretase inhibitors: a focus on the development of small-
molecule inhibitors. Curr. Top. Med. Chem. 2013, 13, 1787-1807.
19. Mandelkow, E. M.; Mandelkow, E. Tau in Alzheimer's disease. Trends Cell Biol. 1998,
8, 425-427.
20. Aguzzi, A.; Haass, C. Games played by rogue proteins in prion disorders and Alzheimer's
disease. Science 2003, 302, 814-818.
21. Zhu, X.; Raina, A. K.; Perry, G.; Smith, M. A. Alzheimer's disease: the two-hit
hypothesis. Lancet Neurol. 2004, 3, 219-226.
22. Wyss-Coray, T.; Rogers, J. Inflammation in Alzheimer disease-a brief review of the basic
science and clinical literature. Cold Spring Harb. Perspect. Med. 2012, 2, a006346.
23. Swerdlow, R. H.; Khan, S. M. A "mitochondrial cascade hypothesis" for sporadic
Alzheimer's disease. Med. Hypotheses 2004, 63, 8-20.
24. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.;
Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med.
Chem. 2008, 51, 347-372.
38
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
38
25. Bolognesi, M. L.; Gandini, A.; Prati, F.; Uliassi, E. From companion diagnostics to
theranostics: a new avenue for Alzheimer's disease? J. Med. Chem. 2016, 59, 7759-7770.
26. Butini, S.; Gabellieri, E.; Brindisi, M.; Giovani, S.; Maramai, S.; Kshirsagar, G.; Guarino,
E.; Brogi, S.; La Pietra, V.; Giustiniano, M.; Marinelli, L.; Novellino, E.; Campiani, G.; Cappelli,
A.; Gemma, S. A stereoselective approach to peptidomimetic BACE1 inhibitors. Eur. J. Med.
Chem. 2013, 70, 233-247.
27. Vila-Real, H.; Coelho, H.; Rocha, J.; Fernandes, A.; Ventura, M. R.; Maycock, C. D.;
Iranzo, O.; Simplicio, A. L. Peptidomimetic beta-secretase inhibitors comprising a sequence of
amyloid-beta peptide for Alzheimer's disease. J. Med. Chem. 2015, 58, 5408-5418.
28. Hattori, Y.; Kobayashi, K.; Deguchi, A.; Nohara, Y.; Akiyama, T.; Teruya, K.; Sanjoh,
A.; Nakagawa, A.; Yamashita, E.; Akaji, K. Evaluation of transition-state mimics in a superior
BACE1 cleavage sequence as peptide-mimetic BACE1 inhibitors. Bioorg. Med. Chem. 2015, 23,
5626-5640.
29. Ghosh, A. K.; Brindisi, M.; Yen, Y. C.; Xu, X.; Huang, X.; Devasamudram, T.; Bilcer,
G.; Lei, H.; Koelsch, G.; Mesecar, A. D.; Tang, J. Structure-based design, synthesis and
biological evaluation of novel beta-secretase inhibitors containing a pyrazole or thiazole moiety
as the P3 ligand. Bioorg. Med. Chem. Lett. 2015, 25, 668-672.
30. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships. J. Med.
Chem. 2006, 49, 7559-7583.
31. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the
development of a central nervous system multiparameter optimization (CNS MPO) approach to
enable alignment of druglike properties. ACS Chem. Neurosci. 2010, 1, 435-449.
39
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
39
32. Caldwell, J. P.; Mazzola, R. D.; Durkin, J.; Chen, J.; Chen, X.; Favreau, L.; Kennedy, M.;
Kuvelkar, R.; Lee, J.; McHugh, N.; McKittrick, B.; Orth, P.; Stamford, A.; Strickland, C.; Voigt,
J.; Wang, L.; Zhang, L.; Zhang, Q.; Zhu, Z. Discovery of potent iminoheterocycle BACE1
inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 5455-5459.
33. Hunt, K. W.; Cook, A. W.; Watts, R. J.; Clark, C. T.; Vigers, G.; Smith, D.; Metcalf, A.
T.; Gunawardana, I. W.; Burkard, M.; Cox, A. A.; Geck Do, M. K.; Dutcher, D.; Thomas, A. A.;
Rana, S.; Kallan, N. C.; DeLisle, R. K.; Rizzi, J. P.; Regal, K.; Sammond, D.; Groneberg, R.;
Siu, M.; Purkey, H.; Lyssikatos, J. P.; Marlow, A.; Liu, X.; Tang, T. P. Spirocyclic beta-site
amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of
cerebrospinal fluid (CSF) amyloid beta in a higher species. J. Med. Chem. 2013, 56, 3379-3403.
34. Thomas, A. A.; Hunt, K. W.; Volgraf, M.; Watts, R. J.; Liu, X.; Vigers, G.; Smith, D.;
Sammond, D.; Tang, T. P.; Rhodes, S. P.; Metcalf, A. T.; Brown, K. D.; Otten, J. N.; Burkard,
M.; Cox, A. A.; Do, M. K.; Dutcher, D.; Rana, S.; DeLisle, R. K.; Regal, K.; Wright, A. D.;
Groneberg, R.; Scearce-Levie, K.; Siu, M.; Purkey, H. E.; Lyssikatos, J. P.; Gunawardana, I. W.
Discovery of 7-tetrahydropyran-2-yl chromans: beta-site amyloid precursor protein cleaving
enzyme 1 (BACE1) inhibitors that reduce amyloid beta-protein (Abeta) in the central nervous
system. J. Med. Chem. 2014, 57, 878-902.
35. Thomas, A. A.; Hunt, K. W.; Newhouse, B.; Watts, R. J.; Liu, X.; Vigers, G.; Smith, D.;
Rhodes, S. P.; Brown, K. D.; Otten, J. N.; Burkard, M.; Cox, A. A.; Geck Do, M. K.; Dutcher,
D.; Rana, S.; DeLisle, R. K.; Regal, K.; Wright, A. D.; Groneberg, R.; Liao, J.; Scearce-Levie,
K.; Siu, M.; Purkey, H. E.; Lyssikatos, J. P. 8-Tetrahydropyran-2-yl chromans: highly selective
beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors. J. Med. Chem. 2014,
57, 10112-10129.
40
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
40
36. Epstein, O.; Bryan, M. C.; Cheng, A. C.; Derakhchan, K.; Dineen, T. A.; Hickman, D.;
Hua, Z.; Human, J. B.; Kreiman, C.; Marx, I. E.; Weiss, M. M.; Wahl, R. C.; Wen, P. H.;
Whittington, D. A.; Wood, S.; Zheng, X. M.; Fremeau, R. T., Jr.; White, R. D.; Patel, V. F. Lead
optimization and modulation of hERG activity in a series of aminooxazoline xanthene beta-site
amyloid precursor protein cleaving enzyme (BACE1) inhibitors. J. Med. Chem. 2014, 57, 9796-
9810.
37. Dineen, T. A.; Chen, K.; Cheng, A. C.; Derakhchan, K.; Epstein, O.; Esmay, J.;
Hickman, D.; Kreiman, C. E.; Marx, I. E.; Wahl, R. C.; Wen, P. H.; Weiss, M. M.; Whittington,
D. A.; Wood, S.; Fremeau, R. T., Jr.; White, R. D.; Patel, V. F. Inhibitors of beta-site amyloid
precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-
methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[ 2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-
8718). J. Med. Chem. 2014, 57, 9811-9831.
38. Chen, J. J.; Liu, Q.; Yuan, C.; Gore, V.; Lopez, P.; Ma, V.; Amegadzie, A.; Qian, W.;
Judd, T. C.; Minatti, A. E.; Brown, J.; Cheng, Y.; Xue, M.; Zhong, W.; Dineen, T. A.; Epstein,
O.; Human, J.; Kreiman, C.; Marx, I.; Weiss, M. M.; Hitchcock, S. A.; Powers, T. S.; Chen, K.;
Wen, P. H.; Whittington, D. A.; Cheng, A. C.; Bartberger, M. D.; Hickman, D.; Werner, J. A.;
Vargas, H. M.; Everds, N. E.; Vonderfecht, S. L.; Dunn, R. T., 2nd; Wood, S.; Fremeau, R. T.,
Jr.; White, R. D.; Patel, V. F. Development of 2-aminooxazoline 3-azaxanthenes as orally
efficacious beta-secretase inhibitors for the potential treatment of Alzheimer's disease. Bioorg.
Med. Chem. Lett. 2015, 25, 767-774.
39. Cheng, Y.; Brown, J.; Judd, T. C.; Lopez, P.; Qian, W.; Powers, T. S.; Chen, J. J.;
Bartberger, M. D.; Chen, K.; Dunn, R. T., 2nd; Epstein, O.; Fremeau, R. T., Jr.; Harried, S.;
Hickman, D.; Hitchcock, S. A.; Luo, Y.; Minatti, A. E.; Patel, V. F.; Vargas, H. M.; Wahl, R. C.;
41
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
41
Weiss, M. M.; Wen, P. H.; White, R. D.; Whittington, D. A.; Zheng, X. M.; Wood, S. An orally
available BACE1 inhibitor that affords robust CNS Abeta reduction without cardiovascular
liabilities. ACS Med. Chem. Lett. 2015, 6, 210-215.
40. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb. J.
Med. Chem. 2008, 51, 817-834.
41. Fielden, M. R.; Werner, J.; Jamison, J. A.; Coppi, A.; Hickman, D.; Dunn, R. T., 2nd;
Trueblood, E.; Zhou, L.; Afshari, C. A.; Lightfoot-Dunn, R. Retinal toxicity induced by a novel
beta-secretase inhibitor in the sprague-dawley rat. Toxicol. Pathol. 2015, 43, 581-592.
42. Mandal, M.; Wu, Y.; Misiaszek, J.; Li, G.; Buevich, A.; Caldwell, J. P.; Liu, X.;
Mazzola, R. D.; Orth, P.; Strickland, C.; Voigt, J.; Wang, H.; Zhu, Z.; Chen, X.; Grzelak, M.;
Hyde, L. A.; Kuvelkar, R.; Leach, P. T.; Terracina, G.; Zhang, L.; Zhang, Q.; Michener, M. S.;
Smith, B.; Cox, K.; Grotz, D.; Favreau, L.; Mitra, K.; Kazakevich, I.; McKittrick, B. A.;
Greenlee, W.; Kennedy, M. E.; Parker, E. M.; Cumming, J. N.; Stamford, A. W. Structure-based
design of an iminoheterocyclic beta-site amyloid precursor protein cleaving enzyme (BACE)
inhibitor that lowers central Abeta in nonhuman primates. J. Med. Chem. 2016, 59, 3231-3248.
43. Mandal, M.; Zhu, Z.; Cumming, J. N.; Liu, X.; Strickland, C.; Mazzola, R. D.; Caldwell,
J. P.; Leach, P.; Grzelak, M.; Hyde, L.; Zhang, Q.; Terracina, G.; Zhang, L.; Chen, X.; Kuvelkar,
R.; Kennedy, M. E.; Favreau, L.; Cox, K.; Orth, P.; Buevich, A.; Voigt, J.; Wang, H.;
Kazakevich, I.; McKittrick, B. A.; Greenlee, W.; Parker, E. M.; Stamford, A. W. Design and
validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1)
inhibitors: conformational constraint to favor a bioactive conformation. J. Med. Chem. 2012, 55,
9331-9345.
42
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
42
44. May, P. C.; Dean, R. A.; Lowe, S. L.; Martenyi, F.; Sheehan, S. M.; Boggs, L. N.; Monk,
S. A.; Mathes, B. M.; Mergott, D. J.; Watson, B. M.; Stout, S. L.; Timm, D. E.; Smith Labell, E.;
Gonzales, C. R.; Nakano, M.; Jhee, S. S.; Yen, M.; Ereshefsky, L.; Lindstrom, T. D.; Calligaro,
D. O.; Cocke, P. J.; Greg Hall, D.; Friedrich, S.; Citron, M.; Audia, J. E. Robust central reduction
of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J.
Neurosci. 2011, 31, 16507-16516.
45. Wu, Y. J.; Guernon, J.; Yang, F.; Snyder, L.; Shi, J.; McClure, A.; Rajamani, R.; Park,
H.; Ng, A.; Lewis, H.; Chang, C.; Camac, D.; Toyn, J. H.; Ahlijanian, M. K.; Albright, C. F.;
Macor, J. E.; Thompson, L. A. Targeting the BACE1 active site flap leads to a potent inhibitor
that elicits robust brain Abeta reduction in rodents. ACS Med. Chem. Lett. 2016, 7, 271-276.
46. Wu, Y. J.; Guernon, J.; Shi, J.; Marcin, L.; Higgins, M.; Rajamani, R.; Muckelbauer, J.;
Lewis, H.; Chang, C.; Camac, D.; Toyn, J. H.; Ahlijanian, M. K.; Albright, C. F.; Macor, J. E.;
Thompson, L. A. Discovery of S3-truncated, C-6 heteroaryl substituted aminothiazine beta-site
APP cleaving enzyme-1 (BACE1) inhibitors. J. Med. Chem. 2016, 59, 8593-8600.
47. Butler, C. R.; Brodney, M. A.; Beck, E. M.; Barreiro, G.; Nolan, C. E.; Pan, F.; Vajdos,
F.; Parris, K.; Varghese, A. H.; Helal, C. J.; Lira, R.; Doran, S. D.; Riddell, D. R.; Buzon, L. M.;
Dutra, J. K.; Martinez-Alsina, L. A.; Ogilvie, K.; Murray, J. C.; Young, J. M.; Atchison, K.;
Robshaw, A.; Gonzales, C.; Wang, J.; Zhang, Y.; O'Neill, B. T. Discovery of a series of
efficient, centrally efficacious BACE1 inhibitors through structure-based drug design. J. Med.
Chem. 2015, 58, 2678-2702.
48. Brodney, M. A.; Beck, E. M.; Butler, C. R.; Barreiro, G.; Johnson, E. F.; Riddell, D.;
Parris, K.; Nolan, C. E.; Fan, Y.; Atchison, K.; Gonzales, C.; Robshaw, A. E.; Doran, S. D.;
Bundesmann, M. W.; Buzon, L.; Dutra, J.; Henegar, K.; LaChapelle, E.; Hou, X.; Rogers, B. N.;
43
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
43
Pandit, J.; Lira, R.; Martinez-Alsina, L.; Mikochik, P.; Murray, J. C.; Ogilvie, K.; Price, L.;
Sakya, S. M.; Yu, A.; Zhang, Y.; O'Neill, B. T. Utilizing structures of CYP2D6 and BACE1
complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious
BACE1 inhibitors. J. Med. Chem. 2015, 58, 3223-3252.
49. May, P. C.; Willis, B. A.; Lowe, S. L.; Dean, R. A.; Monk, S. A.; Cocke, P. J.; Audia, J.
E.; Boggs, L. N.; Borders, A. R.; Brier, R. A.; Calligaro, D. O.; Day, T. A.; Ereshefsky, L.;
Erickson, J. A.; Gevorkyan, H.; Gonzales, C. R.; James, D. E.; Jhee, S. S.; Komjathy, S. F.; Li,
L.; Lindstrom, T. D.; Mathes, B. M.; Martenyi, F.; Sheehan, S. M.; Stout, S. L.; Timm, D. E.;
Vaught, G. M.; Watson, B. M.; Winneroski, L. L.; Yang, Z.; Mergott, D. J. The potent BACE1
inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and
humans. J. Neurosci. 2015, 35, 1199-1210.
50. Winneroski, L. L.; Schiffler, M. A.; Erickson, J. A.; May, P. C.; Monk, S. A.; Timm, D.
E.; Audia, J. E.; Beck, J. P.; Boggs, L. N.; Borders, A. R.; Boyer, R. D.; Brier, R. A.; Hudziak,
K. J.; Klimkowski, V. J.; Garcia Losada, P.; Mathes, B. M.; Stout, S. L.; Watson, B. M.;
Mergott, D. J. Preparation and biological evaluation of conformationally constrained BACE1
inhibitors. Bioorg. Med. Chem. 2015, 23, 3260-3268.
51. Wu, Y. J.; Guernon, J.; Rajamani, R.; Toyn, J. H.; Ahlijanian, M. K.; Albright, C. F.;
Muckelbauer, J.; Chang, C.; Camac, D.; Macor, J. E.; Thompson, L. A. Discovery of furo[2,3-d]
[1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors. Bioorg. Med. Chem.
Lett. 2016, 26, 5729-5731.
52. Wang, Y. S.; Strickland, C.; Voigt, J. H.; Kennedy, M. E.; Beyer, B. M.; Senior, M. M.;
Smith, E. M.; Nechuta, T. L.; Madison, V. S.; Czarniecki, M.; McKittrick, B. A.; Stamford, A.
W.; Parker, E. M.; Hunter, J. C.; Greenlee, W. J.; Wyss, D. F. Application of fragment-based
44
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
44
NMR screening, X-ray crystallography, structure-based design, and focused chemical library
design to identify novel microM leads for the development of nM BACE-1 (beta-site APP
cleaving enzyme 1) inhibitors. J. Med. Chem. 2010, 53, 942-950.
53. Stamford, A. W.; Scott, J. D.; Li, S. W.; Babu, S.; Tadesse, D.; Hunter, R.; Wu, Y.;
Misiaszek, J.; Cumming, J. N.; Gilbert, E. J.; Huang, C.; McKittrick, B. A.; Hong, L.; Guo, T.;
Zhu, Z.; Strickland, C.; Orth, P.; Voigt, J. H.; Kennedy, M. E.; Chen, X.; Kuvelkar, R.; Hodgson,
R.; Hyde, L. A.; Cox, K.; Favreau, L.; Parker, E. M.; Greenlee, W. J. Discovery of an orally
available, brain penetrant BACE1 Inhibitor that affords robust CNS Abeta reduction. ACS Med.
Chem. Lett. 2012, 3, 897-902.
54. http://www.alzforum.org/news/research-news/merck-pulls-plug-phase-23-bace-inhibitor-
trial. (June 7, 2017).
55. Barrow, J. C.; Stauffer, S. R.; Rittle, K. E.; Ngo, P. L.; Yang, Z.; Selnick, H. G.; Graham,
S. L.; Munshi, S.; McGaughey, G. B.; Holloway, M. K.; Simon, A. J.; Price, E. A.;
Sankaranarayanan, S.; Colussi, D.; Tugusheva, K.; Lai, M. T.; Espeseth, A. S.; Xu, M.; Huang,
Q.; Wolfe, A.; Pietrak, B.; Zuck, P.; Levorse, D. A.; Hazuda, D.; Vacca, J. P. Discovery and X-
ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase. J.
Med. Chem. 2008, 51, 6259-6262.
56. Egbertson, M.; McGaughey, G. B.; Pitzenberger, S. M.; Stauffer, S. R.; Coburn, C. A.;
Stachel, S. J.; Yang, W.; Barrow, J. C.; Neilson, L. A.; McWherter, M.; Perlow, D.; Fahr, B.;
Munshi, S.; Allison, T. J.; Holloway, K.; Selnick, H. G.; Yang, Z.; Swestock, J.; Simon, A. J.;
Sankaranarayanan, S.; Colussi, D.; Tugusheva, K.; Lai, M. T.; Pietrak, B.; Haugabook, S.; Jin,
L.; Chen, I. W.; Holahan, M.; Stranieri-Michener, M.; Cook, J. J.; Vacca, J.; Graham, S. L.
45
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
45
Methyl-substitution of an iminohydantoin spiropiperidine beta-secretase (BACE-1) inhibitor has
a profound effect on its potency. Bioorg. Med. Chem. Lett. 2015, 25, 4812-4819.
57. Rombouts, F. J.; Tresadern, G.; Delgado, O.; Martinez-Lamenca, C.; Van Gool, M.;
Garcia-Molina, A.; Alonso de Diego, S. A.; Oehlrich, D.; Prokopcova, H.; Alonso, J. M.; Austin,
N.; Borghys, H.; Van Brandt, S.; Surkyn, M.; De Cleyn, M.; Vos, A.; Alexander, R.; Macdonald,
G.; Moechars, D.; Gijsen, H.; Trabanco, A. A. 1,4-Oxazine beta-secretase 1 (BACE1) inhibitors:
from hit generation to orally bioavailable brain penetrant leads. J. Med. Chem. 2015, 58, 8216-
8235.
58. Cheng, Y.; Judd, T. C.; Bartberger, M. D.; Brown, J.; Chen, K.; Fremeau, R. T., Jr.;
Hickman, D.; Hitchcock, S. A.; Jordan, B.; Li, V.; Lopez, P.; Louie, S. W.; Luo, Y.; Michelsen,
K.; Nixey, T.; Powers, T. S.; Rattan, C.; Sickmier, E. A.; St Jean, D. J., Jr.; Wahl, R. C.; Wen, P.
H.; Wood, S. From fragment screening to in vivo efficacy: optimization of a series of 2-
aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1
(BACE1). J. Med. Chem. 2011, 54, 5836-5857.
59. Jordan, J. B.; Whittington, D. A.; Bartberger, M. D.; Sickmier, E. A.; Chen, K.; Cheng,
Y.; Judd, T. Fragment-linking approach using (19)F NMR spectroscopy to obtain highly potent
and selective inhibitors of beta-secretase. J. Med. Chem. 2016, 59, 3732-3749.
60. Boy, K. M.; Guernon, J. M.; Wu, Y. J.; Zhang, Y.; Shi, J.; Zhai, W.; Zhu, S.; Gerritz, S.
W.; Toyn, J. H.; Meredith, J. E.; Barten, D. M.; Burton, C. R.; Albright, C. F.; Good, A. C.;
Grace, J. E.; Lentz, K. A.; Olson, R. E.; Macor, J. E.; Thompson, L. A., 3rd. Macrocyclic
prolinyl acyl guanidines as inhibitors of beta-secretase (BACE). Bioorg. Med. Chem. Lett. 2015,
25, 5040-5047.
46
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
46
61. Liu, P.; Niu, Y.; Wang, C.; Sun, Q.; Zhai, Y.; Yu, J.; Sun, J.; Xu, F.; Yan, G.; Huang, W.;
Liang, L.; Xu, P. 4-Oxo-1,4-dihydro-quinoline-3-carboxamides as BACE-1 inhibitors: synthesis,
biological evaluation and docking studies. Eur. J. Med. Chem. 2014, 79, 413-421.
62. Razzaghi-Asl, N.; Firuzi, O.; Hemmateenejad, B.; Javidnia, K.; Edraki, N.; Miri, R.
Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines
as small molecule BACE-1 inhibitors. Bioorg. Med. Chem. 2013, 21, 6893-6909.
63. Jain, P.; Wadhwa, P. K.; Rohilla, S.; Jadhav, H. R. Rational design, synthesis and in vitro
evaluation of allylidene hydrazinecarboximidamide derivatives as BACE-1 inhibitors. Bioorg.
Med. Chem. Lett. 2016, 26, 33-37.
64. Jain, P.; Wadhwa, P. K.; Gunapati, S.; Jadhav, H. R. Design, synthesis and in vitro
evaluation studies of sulfonyl-amino-acetamides as small molecule BACE-1 inhibitors. Bioorg.
Med. Chem. 2016, 24, 2567-2575.
65. De Tran, Q.; Bepary, S.; Lee, G. H.; Cho, H.; Park, W. K.; Lim, H. J. Synthesis of
(3S,4S)-4-aminopyrrolidine-3-ol derivatives and biological evaluation for their BACE1
inhibitory activities. Bioorg. Med. Chem. Lett. 2016, 26, 51-54.
66. Kacker, P.; Bottegoni, G.; Cavalli, A. Computational methods in the discovery and
design of BACE-1 inhibitors. Curr. Med. Chem. 2012, 19, 6095-6111.
67. Hernández-Rodríguez, M.; Correa-Basurto, J.; Gutiérrez, A.; Vitorica, J.; Rosales-
Hernández, M. C. Asp32 and Asp228 determine the selective inhibition of BACE1 as shown by
docking and molecular dynamics simulations. Eur. J. Med. Chem. 2016, 124, 1142-1154.
68. Protein Data Bank. www.rcsb.org (February 1, 2017).
47
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
47
69. Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R. Four-dimensional docking: a fast
and accurate account of discrete receptor flexibility in ligand docking. J. Med. Chem. 2009, 52,
397-406.
70. Craig, I. R.; Essex, J. W.; Spiegel, K. Ensemble docking into multiple
crystallographically derived protein structures: an evaluation based on the statistical analysis of
enrichments. J. Chem. Inf. Model. 2010, 50, 511-524.
71. Limongelli, V.; Marinelli, L.; Cosconati, S.; Braun, H. A.; Schmidt, B.; Novellino, E.
Ensemble-docking approach on BACE-1: pharmacophore perception and guidelines for drug
design. ChemMedChem 2007, 2, 667-678.
72. Cosconati, S.; Marinelli, L.; Di Leva, F. S.; La Pietra, V.; De Simone, A.; Mancini, F.;
Andrisano, V.; Novellino, E.; Goodsell, D. S.; Olson, A. J. Protein flexibility in virtual
screening: the BACE-1 case study. J. Chem. Inf. Model. 2012, 52, 2697-2704.
73. Dominguez, J. L.; Christopeit, T.; Villaverde, M. C.; Gossas, T.; Otero, J. M.; Nystrom,
S.; Baraznenok, V.; Lindstrom, E.; Danielson, U. H.; Sussman, F. Effect of the protonation state
of the titratable residues on the inhibitor affinity to BACE-1. Biochemistry 2010, 49, 7255-7263.
74. Polgar, T.; Keseru, G. M. Virtual screening for beta-secretase (BACE1) inhibitors reveals
the importance of protonation states at Asp32 and Asp228. J. Med. Chem. 2005, 48, 3749-3755.
75. Barman, A.; Prabhakar, R. Protonation states of the catalytic dyad of beta-secretase
(BACE1) in the presence of chemically diverse inhibitors: a molecular docking study. J. Chem.
Inf. Model. 2012, 52, 1275-1287.
76. Dominguez, J. L.; Villaverde, M. C.; Sussman, F. Effect of pH and ligand charge state on
BACE-1 fragment docking performance. J. Comput. -Aided Mol. Des. 2013, 27, 403-417.
48
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
48
77. Bottegoni, G.; Veronesi, M.; Bisignano, P.; Kacker, P.; Favia, A. D.; Cavalli, A.
Development and application of a virtual screening protocol for the identification of multitarget
fragments. ChemMedChem 2016, 11, 1259-1263.
78. Kacker, P.; Masetti, M.; Mangold, M.; Bottegoni, G.; Cavalli, A. Combining dyad
protonation and active site plasticity in BACE-1 structure-based drug design. J. Chem. Inf.
Model. 2012, 52, 1079-1085.
79. Silvestri, R. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors
for the treatment of Alzheimer's disease. Med. Res. Rev. 2009, 29, 295-338.
80. Park, H.; Lee, S. Determination of the active site protonation state of beta-secretase from
molecular dynamics simulation and docking experiment: implications for structure-based
inhibitor design. J. Am. Chem. Soc. 2003, 125, 16416-16422.
81. Mongan, J.; Case, D. A.; McCammon, J. A. Constant pH molecular dynamics in
generalized Born implicit solvent. J. Comput. Chem. 2004, 25, 2038-2048.
82. Itoh, S. G.; Damjanović, A.; Brooks, B. R. pH replica-exchange method based on discrete
protonation states. Proteins: Struct. Funct. Bioinfom. 2011, 79, 3420-3436.
83. Swails, J. M.; Roitberg, A. E. Enhancing conformation and protonation state sampling of
hen egg white lysozyme using pH replica exchange molecular dynamics. J. Chem. Theory
Comput. 2012, 8, 4393-4404.
84. Ellis, C. R.; Shen, J. pH-dependent population shift regulates BACE1 activity and
inhibition. J. Am. Chem. Soc. 2015, 137, 9543-9546.
85. Kim, M. O.; Blachly, P. G.; McCammon, J. A. Conformational dynamics and binding
free energies of inhibitors of BACE-1: from the perspective of protonation equilibria. PLoS
Comput. Biol. 2015, 11, e1004341.
49
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
49
86. Ellis, C. R.; Tsai, C.-C.; Hou, X.; Shen, J. Constant pH molecular dynamics reveals pH-
modulated binding of two small-molecule BACE1 inhibitors. J. Phys. Chem. Lett. 2016, 7, 944-
949.
87. Chodera, J. D.; Mobley, D. L.; Shirts, M. R.; Dixon, R. W.; Branson, K.; Pande, V. S.
Alchemical free energy methods for drug discovery: progress and challenges. Curr. Opin. Struct.
Biol. 2011, 21, 150-160.
88. Ciordia, M.; Pérez-Benito, L.; Delgado, F.; Trabanco, A. A.; Tresadern, G. Application
of free energy perturbation for the design of BACE1 inhibitors. J. Chem. Inf. Model. 2016, 56,
1856-1871.
89. Keranen, H.; Perez-Benito, L.; Ciordia, M.; Delgado, F.; Steinbrecher, T. B.; Oehlrich,
D.; van Vlijmen, H. W.; Trabanco, A. A.; Tresadern, G. Acylguanidine beta secretase 1
inhibitors: a combined experimental and free energy perturbation study. J. Chem. Theory
Comput. 2017.
90. De Vivo, M.; Masetti, M.; Bottegoni, G.; Cavalli, A. Role of molecular dynamics and
related methods in drug discovery. J. Med. Chem. 2016, 59, 4035-4061.
91. Wang, L.; Wu, Y.; Deng, Y.; Kim, B.; Pierce, L.; Krilov, G.; Lupyan, D.; Robinson, S.;
Dahlgren, M. K.; Greenwood, J.; Romero, D. L.; Masse, C.; Knight, J. L.; Steinbrecher, T.;
Beuming, T.; Damm, W.; Harder, E.; Sherman, W.; Brewer, M.; Wester, R.; Murcko, M.; Frye,
L.; Farid, R.; Lin, T.; Mobley, D. L.; Jorgensen, W. L.; Berne, B. J.; Friesner, R. A.; Abel, R.
Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery
by way of a modern free-energy calculation protocol and force field. J. Am. Chem. Soc. 2015,
137, 2695-2703.
50
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
50
92. Cavalli, A.; Spitaleri, A.; Saladino, G.; Gervasio, F. L. Investigating drug-target
association and dissociation mechanisms using metadynamics-based algorithms. Acc. Chem. Res.
2015, 48, 277-285.
93. Melchiorre, C.; Andrisano, V.; Bolognesi, M. L.; Budriesi, R.; Cavalli, A.; Cavrini, V.;
Rosini, M.; Tumiatti, V.; Recanatini, M. Acetylcholinesterase noncovalent inhibitors based on a
polyamine backbone for potential use against Alzheimer's disease. J. Med. Chem. 1998, 41,
4186-4189.
94. Prati, F.; De Simone, A.; Bisignano, P.; Armirotti, A.; Summa, M.; Pizzirani, D.;
Scarpelli, R.; Perez, D. I.; Andrisano, V.; Perez-Castillo, A.; Monti, B.; Massenzio, F.; Polito, L.;
Racchi, M.; Favia, A. D.; Bottegoni, G.; Martinez, A.; Bolognesi, M. L.; Cavalli, A. Multitarget
drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3beta inhibitors.
Angew. Chem. Int. Ed. Engl. 2015, 54, 1578-1582.
95. Prati, F.; De Simone, A.; Armirotti, A.; Summa, M.; Pizzirani, D.; Scarpelli, R.; Bertozzi,
S. M.; Perez, D. I.; Andrisano, V.; Perez-Castillo, A.; Monti, B.; Massenzio, F.; Polito, L.;
Racchi, M.; Sabatino, P.; Bottegoni, G.; Martinez, A.; Cavalli, A.; Bolognesi, M. L. 3,4-
Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1/GSK-3beta fragment hits against
Alzheimer's disease. ACS Chem. Neurosci. 2015, 6, 1665-1682.
96. Di Martino, R. M.; De Simone, A.; Andrisano, V.; Bisignano, P.; Bisi, A.; Gobbi, S.;
Rampa, A.; Fato, R.; Bergamini, C.; Perez, D. I.; Martinez, A.; Bottegoni, G.; Cavalli, A.;
Belluti, F. Versatility of the curcumin scaffold: discovery of potent and balanced dual BACE-1
and GSK-3beta inhibitors. J. Med. Chem. 2016, 59, 531-544.
97. Baell, J. B. Feeling nature's PAINS: natural products, natural product drugs, and pan
assay interference compounds (PAINS). J. Nat. Prod. 2016, 79, 616-628.
51
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
51
98. Leinonen, A.; Koponen, M.; Hartikainen, S. Systematic review: representativeness of
participants in RCTs of acetylcholinesterase inhibitors. PLoS One 2015, 10, e0124500.
99. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.;
Andrisano, V.; Rampa, A. Multi-target-directed coumarin derivatives: hAChE and BACE1
inhibitors as potential anti-Alzheimer compounds. Bioorg. Med. Chem. Lett. 2008, 18, 423-426.
100. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.;
Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-
dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and
acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's
disease therapy. J. Med. Chem. 2003, 46, 2279-2282.
101. Belluti, F.; De Simone, A.; Tarozzi, A.; Bartolini, M.; Djemil, A.; Bisi, A.; Gobbi, S.;
Montanari, S.; Cavalli, A.; Andrisano, V.; Bottegoni, G.; Rampa, A. Fluorinated benzophenone
derivatives: balanced multipotent agents for Alzheimer's disease. Eur. J. Med. Chem. 2014, 78,
157-166.
102. Rampa, A.; Mancini, F.; De Simone, A.; Falchi, F.; Belluti, F.; Di Martino, R. M.; Gobbi,
S.; Andrisano, V.; Tarozzi, A.; Bartolini, M.; Cavalli, A.; Bisi, A. From AChE to BACE1
inhibitors: the role of the amine on the indanone scaffold. Bioorg. Med. Chem. Lett. 2015, 25,
2804-2808.
103. Zha, X.; Lamba, D.; Zhang, L.; Lou, Y.; Xu, C.; Kang, D.; Chen, L.; Xu, Y.; Zhang, L.;
De Simone, A.; Samez, S.; Pesaresi, A.; Stojan, J.; Lopez, M. G.; Egea, J.; Andrisano, V.;
Bartolini, M. Novel tacrine-benzofuran hybrids as potent multitarget-directed ligands for the
treatment of Alzheimer's disease: design, synthesis, biological evaluation, and X-ray
crystallography. J. Med. Chem. 2016, 59, 114-131.
52
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
52
104. Costanzo, P.; Cariati, L.; Desiderio, D.; Sgammato, R.; Lamberti, A.; Arcone, R.;
Salerno, R.; Nardi, M.; Masullo, M.; Oliverio, M. Design, synthesis, and evaluation of
donepezil-like compounds as AChE and BACE-1 inhibitors. ACS Med. Chem. Lett. 2016, 7, 470-
475.
105. Zhu, Y.; Xiao, K.; Ma, L.; Xiong, B.; Fu, Y.; Yu, H.; Wang, W.; Wang, X.; Hu, D.; Peng,
H.; Li, J.; Gong, Q.; Chai, Q.; Tang, X.; Zhang, H.; Li, J.; Shen, J. Design, synthesis and
biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. Bioorg.
Med. Chem. 2009, 17, 1600-1613.
106. Camps, P.; Formosa, X.; Galdeano, C.; Munoz-Torrero, D.; Ramirez, L.; Gomez, E.;
Isambert, N.; Lavilla, R.; Badia, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.;
Arce, M. P.; Rodriguez-Franco, M. I.; Huertas, O.; Dafni, T.; Luque, F. J. Pyrano[3,2-
c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-
directed anti-Alzheimer compounds. J. Med. Chem. 2009, 52, 5365-5379.
107. Huang, W.; Tang, L.; Shi, Y.; Huang, S.; Xu, L.; Sheng, R.; Wu, P.; Li, J.; Zhou, N.; Hu,
Y. Searching for the multi-target-directed ligands against Alzheimer's disease: discovery of
quinoxaline-based hybrid compounds with AChE, H(3)R and BACE 1 inhibitory activities.
Bioorg. Med. Chem. 2011, 19, 7158-7167.
108. Viayna, E.; Sola, I.; Bartolini, M.; De Simone, A.; Tapia-Rojas, C.; Serrano, F. G.;
Sabate, R.; Juarez-Jimenez, J.; Perez, B.; Luque, F. J.; Andrisano, V.; Clos, M. V.; Inestrosa, N.
C.; Munoz-Torrero, D. Synthesis and multitarget biological profiling of a novel family of rhein
derivatives as disease-modifying anti-Alzheimer agents. J. Med. Chem. 2014, 57, 2549-2567.
53
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
53
109. Oudin, A.; Forsberg, B.; Adolfsson, A. N.; Lind, N.; Modig, L.; Nordin, M.; Nordin, S.;
Adolfsson, R.; Nilsson, L. G. Traffic-related air pollution and dementia incidence in northern
sweden: a longitudinal study. Environ. Health Perspect. 2016, 124, 306-312.
110. Moulton, P. V.; Yang, W. Air pollution, oxidative stress, and Alzheimer's disease. J.
Environ. Public Health 2012, 2012, 472751.
111. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.;
Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature
of Alzheimer's disease. Angew. Chem. Int. Ed. Engl. 2007, 46, 3689-3692.
112. Capurro, V.; Busquet, P.; Lopes, J. P.; Bertorelli, R.; Tarozzo, G.; Bolognesi, M. L.;
Piomelli, D.; Reggiani, A.; Cavalli, A. Pharmacological characterization of memoquin, a multi-
target compound for the treatment of Alzheimer's disease. PLoS One 2013, 8, e56870.
113. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay
interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J.
Med. Chem. 2010, 53, 2719-2740.
114. Nelson, K. M.; Dahlin, J. L.; Bisson, J.; Graham, J.; Pauli, G. F.; Walters, M. A. The
essential medicinal chemistry of curcumin. J. Med. Chem. 2017, 60, 1620-1637.
115. https://www.scientificamerican.com/article/alzheimer-rsquo-s-drug-fails-in-another-
crushing-disappointment/. (June 7, 2017).
54
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
54
Figure 1. Advanced Merck’s BACE-1 inhibitor 1.
55
1219122012211222
55
Figure 2. Aminohydantoin 2.
56
1223
1224
1225
56
Figure 3. Spirocyclic aminohydantoins 3 and 4.
57
1226
1227
1228
57
Figure 4. Spirocyclic aminohydantoin 5.
58
1229
1230
1231
58
Figure 5. Spirocyclic aminooxazoline 6.
59
1232
1233
1234
59
Figure 6. Spirocyclic aminooxazolines 7-11.
60
1235
1236
1237
60
Figure 7. Iminopyrimidinones 12 and 13.
61
1238
1239
1240
61
Figure 8. Aminothiazines 14-22.
62
1241
1242
62
Figure 9. Aminothiazines 23, 27 and 28.
63
1243
1244
1245
63
Figure 10. Aminothiazines 24-26.
64
1246
1247
1248
64
Figure 11. Iminopyrimidinone 29 and iminothiadiazinane dioxide 30.
65
1249125012511252
65
Figure 12. Spiropiperidine iminohydantoins 31 and 32.
66
1253
1254
1255
1256
66
Figure 13. Aminoxazine 33.
67
1257
1258
1259
67
Figure 14. Aminoquinoline 34 design rationale.
68
1260
1261
1262
68
Figure 15. Cyclic acyl guanidine 37.
69
1263
1264
1265
69
Figure 16. Examples of BACE-1 inhibitors (38-43) discovered employing computer-assisted drug discovery methods.
70
1266
12671268126912701271
70
Figure 17. Dual binding site AchE inhibitor 44, and dual BACE-1/AChE inhibitors 45-49.
71
1272
1273
1274
1275
71
Figure 18. Dual BACE-1/GSK-3 triazinone inhibitor 50.
72
1276
1277
1278
72
Figure 19. Dual BACE-1/GSK-3 curcumin inhibitor 51.
73
1279
1280
1281
73
TOC Graphic
74
1282
1283
1284
1285
74
Top Related